[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Biom'up\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":158},{"warningLetters":4,"total":157},[5,32,53,73,94,116,137],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},20,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-13T04:00:00Z\">07\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomylz-pvt-ltd-729483-07132026\">BioMylz Pvt. Ltd. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-103\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vasanth Samaga\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder-Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BioMylz Pvt. Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan># cj-1, Santra Magan Place Apartment off Banneraghatta Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Doddakammanahalli, near Maruthi Dental College\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bangalore\u003C\u002Fspan> \u003Cspan>560076\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-103\u003C\u002Fp>\u003Cp>July 13, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Samaga:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, BioMylz Pvt. Ltd., FEI 3013697420, at #21 - D #21 - D Building No 1, Bengaluru, Karnataka, India, from February 4 to 9, 2026.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, violations were identified and documented during a review of your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS). Based on our review, you failed to provide complete drug listing information for your Soraresal Cream, NDC 73526-002, and Equate Medicated Vaporizing Steam Liquid, NDC 73559-011, as required under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j). Failure to provide complete listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). Furthermore, these drugs are misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your February 27, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture an over-the counter (OTC) drug product, a topical psoriasis cream, for the U.S market.\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to ensure that all CGMP records were retained and available for review. Our investigators discovered a garbage bag containing original data. The recovered documents included, but were not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>executed production batch records\u003C\u002Fli>\u003Cli>media preparation\u003C\u002Fli>\u003Cli>incubation and sterilization cycle logbook pages\u003C\u002Fli>\u003Cli>finished product sample collection forms\u003C\u002Fli>\u003Cli>environmental monitoring sample forms\u003C\u002Fli>\u003Cli>product complaint and change control log forms\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, your firm failed to maintain complete laboratory records, including original data for laboratory analyses conducted on commercial drug products. Specifically, you did not retain original data supporting laboratory test results used to release commercial batches, and you were not able to make this data available for FDA review.\u003C\u002Fp>\u003Cp>Furthermore, you did not adequately control laboratory logbooks. Your logbooks had unnumbered pages and lacked reconciliation, and you did not permanently and contemporaneously document original data. For example, your personnel used a pencil to initially record volume entries and subsequently overwrote them in ink after completion of the weight check activity.\u003C\u002Fp>\u003Cp>In your response, you attributed the torn documents to the actions of a former employee (ex-plant manager) who made false entries to intentionally increase yield. You also stated that this was an isolated and exceptional incident with no identified impact on approved or controlled documents and that the employee was terminated. However, your statement in the response is contradicted by the evidence provided to our investigators. This evidence indicates that the manager had been repeatedly observed on multiple occasions violating data integrity practices including, but not limited to, destruction of batch production records, destruction of laboratory-controlled records, and falsification of production and laboratory data.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not address your egregious and persistent data integrity issues, nor did you provide any detailed or systemic remediations. You also did not conduct a comprehensive evaluation of the manufacturing and laboratory records to determine the impact of the data integrity breeches on the quality of your OTC drug products manufactured for the U.S. market.\u003C\u002Fp>\u003Cp>All testing records and raw data must be handled appropriately and in accordance with established procedures. Your response fails to describe immediate corrective actions to prevent the alteration or destruction of CGMP data.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents:\u003Cbr>• \u003Cem>ICH Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload\u003Cbr>• \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload,\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>Reliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests and manufacturing activities. The lack of complete data compromises the ability of the QU to exercise its function of ensuring compliance to applicable standards.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain an independent qualified third-party consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies.\u003Cbr>o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate adequate validation of your manufacturing process. You were unable to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> processes assure \u003Cstrong>(b)(4)\u003C\u002Fstrong> after commercial scale-up of your process. For example, critical control process parameters such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not adequately documented in batch records. Furthermore, you did not conduct adequate in-process hold time studies and stability studies to support shelf life.\u003C\u002Fp>\u003Cp>You also failed to adequately demonstrate the effectiveness of your cleaning procedures to ensure the removal of active pharmaceutical ingredient (API) residue, as well as control of potential microbial contamination from your shared manufacturing equipment after the scale-up.\u003C\u002Fp>\u003Cp>Your response indicates that process and cleaning validation were performed in 2019 prior to the commercial scale-up, and you commit to performing process validation for the upcoming commercial orders. Additionally, you stated that cleaning validation studies, including residue limit calculations and worst-case assessments, have been conducted and documented. However, your response is inadequate. You lack supporting documentation for both activities, and you did not provide a timeline for completing the re-validation following commercial scale-up.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drug products.\u003C\u002Fp>\u003Cp>Also, process qualification studies characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established. They include intensive monitoring and testing throughout each significant process stage (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>batch formulation and filling).\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem>, for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced prior to performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocols, and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make their manufacturing equipment difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fli>\u003Cli>A description of the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure components and drug products are adequately monitored for microbiological contamination. For example, your topical psoriasis cream does not include testing for the presence of objectionable microorganisms, such as \u003Cem>Staphylococcus aureus\u003C\u002Fem> and \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem>, critical for cutaneous products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You and your customer Atrimed Pharmaceuticals Private Limited have a quality agreement regarding the manufacture of the U.S. marketed Soraresal Cream OTC drug product.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510(j) of the FD&amp;C Act and 21 CFR Part 207 set forth the requirements for the listing of drugs. Under section 510(j)(1) of the FD&amp;C Act and 21 CFR 207.49(a)(12), a registrant must provide the name and Unique Facility Identifier of every other establishment where manufacturing is performed for a drug and the type of operation performed at each such establishment. Under 21 CFR 207.1, “manufacture” includes manipulation, sampling, testing, or control procedures applied to the final product or to any part of the process, including, for example, analytical testing of drugs for another registered establishment’s drug. Upon review of your firm’s drug listings, it was found that you failed to include \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your drug listing for Soraresal Cream, NDC 73526-002, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your drug listing for Equate Medicated Vaporizing Steam Liquid, NDC 73559-011, as required by 21 CFR 207.49(a)(12). Failure to provide listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Further, because \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed release testing, which constitutes manufacturing under 21 CFR 207.1, they were required to be registered with FDA under 21 CFR 207.17(a). A search of eDRLS confirms that neither laboratory is registered with FDA. Accordingly, Soraresal Cream and Equate Medicated Vaporizing Steam Liquid were manufactured, in part, in establishments not duly registered with FDA. Under section 502(o) of the FD&amp;C Act, a drug is misbranded if it was manufactured in an establishment not duly registered under section 510, or if it was not included in a list required by section 510(j). Under section 301(a), it is a prohibited act to introduce or deliver for introduction into interstate commerce any drug that is misbranded.\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at BioMylz Pvt. Ltd., located at #21 - D #21 - D Building No 1, Bengaluru, Karnataka, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013697420 and ATTN: Frank Wackes.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-103\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vasanth Samaga\n\nRecipient Title\n\nFounder-Director\n\nBioMylz Pvt. Ltd.\n\n# cj-1, Santra Magan Place Apartment off Banneraghatta Road\n\nDoddakammanahalli, near Maruthi Dental College\n\nBangalore 560076\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-103\nJuly 13, 2026\nDear Mr. Samaga:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, BioMylz Pvt. Ltd., FEI 3013697420, at #21 - D #21 - D Building No 1, Bengaluru, Karnataka, India, from February 4 to 9, 2026.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, violations were identified and documented during a review of your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS). Based on our review, you failed to provide complete drug listing information for your Soraresal Cream, NDC 73526-002, and Equate Medicated Vaporizing Steam Liquid, NDC 73559-011, as required under section 510(j) of the FD&C Act, 21 U.S.C. 360(j). Failure to provide complete listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). Furthermore, these drugs are misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introducing or delivering these products for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nCGMP Violations\nWe reviewed your February 27, 2026, response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supporting documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYou manufacture an over-the counter (OTC) drug product, a topical psoriasis cream, for the U.S market.\nYour quality unit (QU) failed to ensure that all CGMP records were retained and available for review. Our investigators discovered a garbage bag containing original data. The recovered documents included, but were not limited to:\nexecuted production batch records\nmedia preparation\nincubation and sterilization cycle logbook pages\nfinished product sample collection forms\nenvironmental monitoring sample forms\nproduct complaint and change control log forms\nAdditionally, your firm failed to maintain complete laboratory records, including original data for laboratory analyses conducted on commercial drug products. Specifically, you did not retain original data supporting laboratory test results used to release commercial batches, and you were not able to make this data available for FDA review.\nFurthermore, you did not adequately control laboratory logbooks. Your logbooks had unnumbered pages and lacked reconciliation, and you did not permanently and contemporaneously document original data. For example, your personnel used a pencil to initially record volume entries and subsequently overwrote them in ink after completion of the weight check activity.\nIn your response, you attributed the torn documents to the actions of a former employee (ex-plant manager) who made false entries to intentionally increase yield. You also stated that this was an isolated and exceptional incident with no identified impact on approved or controlled documents and that the employee was terminated. However, your statement in the response is contradicted by the evidence provided to our investigators. This evidence indicates that the manager had been repeatedly observed on multiple occasions violating data integrity practices including, but not limited to, destruction of batch production records, destruction of laboratory-controlled records, and falsification of production and laboratory data.\nYour response is inadequate. You did not address your egregious and persistent data integrity issues, nor did you provide any detailed or systemic remediations. You also did not conduct a comprehensive evaluation of the manufacturing and laboratory records to determine the impact of the data integrity breeches on the quality of your OTC drug products manufactured for the U.S. market.\nAll testing records and raw data must be handled appropriately and in accordance with established procedures. Your response fails to describe immediate corrective actions to prevent the alteration or destruction of CGMP data.\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents:\n• ICH Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload\n• Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload,\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nReliability of data is compromised when there is a failure to maintain complete records of the conditions and data associated with all tests and manufacturing activities. The lack of complete data compromises the ability of the QU to exercise its function of ensuring compliance to applicable standards.\nWe strongly recommend that you retain an independent qualified third-party consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies.\no A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\nYou failed to demonstrate adequate validation of your manufacturing process. You were unable to demonstrate that your (b)(4) processes assure (b)(4) after commercial scale-up of your process. For example, critical control process parameters such as (b)(4) were not adequately documented in batch records. Furthermore, you did not conduct adequate in-process hold time studies and stability studies to support shelf life.\nYou also failed to adequately demonstrate the effectiveness of your cleaning procedures to ensure the removal of active pharmaceutical ingredient (API) residue, as well as control of potential microbial contamination from your shared manufacturing equipment after the scale-up.\nYour response indicates that process and cleaning validation were performed in 2019 prior to the commercial scale-up, and you commit to performing process validation for the upcoming commercial orders. Additionally, you stated that cleaning validation studies, including residue limit calculations and worst-case assessments, have been conducted and documented. However, your response is inadequate. You lack supporting documentation for both activities, and you did not provide a timeline for completing the re-validation following commercial scale-up.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drug products.\nAlso, process qualification studies characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established. They include intensive monitoring and testing throughout each significant process stage (e.g., (b)(4)batch formulation and filling).\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, Process Validation: General Principles and Practices, for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\nA timeline for performing appropriate process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced prior to performing any process validation studies.\nProcess performance protocols, and written procedures for qualification of equipment and facilities.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make their manufacturing equipment difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nA description of the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYou failed to ensure components and drug products are adequately monitored for microbiological contamination. For example, your topical psoriasis cream does not include testing for the presence of objectionable microorganisms, such as Staphylococcus aureus and Pseudomonas aeruginosa, critical for cutaneous products.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, we strongly recommend that your firm engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou and your customer Atrimed Pharmaceuticals Private Limited have a quality agreement regarding the manufacture of the U.S. marketed Soraresal Cream OTC drug product.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nDrug Listing Violations\nSection 510(j) of the FD&C Act and 21 CFR Part 207 set forth the requirements for the listing of drugs. Under section 510(j)(1) of the FD&C Act and 21 CFR 207.49(a)(12), a registrant must provide the name and Unique Facility Identifier of every other establishment where manufacturing is performed for a drug and the type of operation performed at each such establishment. Under 21 CFR 207.1, “manufacture” includes manipulation, sampling, testing, or control procedures applied to the final product or to any part of the process, including, for example, analytical testing of drugs for another registered establishment’s drug. Upon review of your firm’s drug listings, it was found that you failed to include (b)(4) in your drug listing for Soraresal Cream, NDC 73526-002, and (b)(4) in your drug listing for Equate Medicated Vaporizing Steam Liquid, NDC 73559-011, as required by 21 CFR 207.49(a)(12). Failure to provide listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act.\nFurther, because (b)(4) performed release testing, which constitutes manufacturing under 21 CFR 207.1, they were required to be registered with FDA under 21 CFR 207.17(a). A search of eDRLS confirms that neither laboratory is registered with FDA. Accordingly, Soraresal Cream and Equate Medicated Vaporizing Steam Liquid were manufactured, in part, in establishments not duly registered with FDA. Under section 502(o) of the FD&C Act, a drug is misbranded if it was manufactured in an establishment not duly registered under section 510, or if it was not included in a list required by section 510(j). Under section 301(a), it is a prohibited act to introduce or deliver for introduction into interstate commerce any drug that is misbranded.\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\nIt is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR Part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at BioMylz Pvt. Ltd., located at #21 - D #21 - D Building No 1, Bengaluru, Karnataka, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013697420 and ATTN: Frank Wackes.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research","BioMylz Pvt. Ltd.","biomylz-pvt-ltd-729483-07132026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomylz-pvt-ltd-729483-07132026","2026-10-26T08:08:05.21894+00:00","Warning Letter","Issued","2026-07-21","729483","Drugs Over-the-Counter Drugs","Mr. Vasanth Samaga","2026-08-19T04:28:37.646+00:00","VIA UPS","320-26-103","2026-07-13",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":47,"medical_device_id":19,"response_letter_date":19},2694,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-05-04T12:40:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-04T04:00:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomd-plus-llc-618460-05042022\">BioMD Plus LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded\u002FCannabidiol (CBD) Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan M. Levitt\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BioMD Plus LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1371 Sheffield Pkwy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Marietta\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30062\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@biomdplus.com\"> support@biomdplus.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>May 4, 2022\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>RE: #618460\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Dear Jonathan Levitt:\u003Cb> \u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.biomdplus.com in February 2022 and has determined that you take orders there for various human and animal products, which you represent as containing cannabidiol (CBD) or Delta-8 tetrahydrocannabinol (THC). \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>We have also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002FbioMDplus\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>, https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F and\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F, which\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> direct consumers to your website \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>www.biomdplus.com to\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>purchase your products. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>The claims on your website and social media accounts establish that your products, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>some of which are available in multiple varieties, “CBD Oil,” “CBD Capsules,” “Vegan CBD Gummies,” “CBD Pain Relief Cream,” “Delta 8 THC Gummies,” and “Delta 8 THC Vape Cartridge” (hereinafter referred to as “your CBD and Delta-8 THC products for humans”) are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1). &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, your “Natural Pet CBD Oil” is an unapproved new animal drug that is unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and is adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5).&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA has also determined that certain food products that you market are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find specific information about how FDA regulates cannabis-derived products at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Over the past several years, FDA has warned the public on various illegally marketed CBD-containing products. FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Dietary Supplement Labeling\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Information on your website at www.biomdplus.com\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>indicates that you appear to market your CBD-containing “CBD Capsules” and “Vegan CBD Gummies” as dietary supplements. For example, the product webpages display a product label image with “hemp supplement” on them. However, your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act, 21 U.S.C. 321(ff). FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii). Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, but you may present FDA with any evidence that has bearing on this issue.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Unapproved New Human Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Based on a review of your website and social media accounts, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>your CBD and Delta-8 THC products for humans \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>are\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Examples of claims from your website www.biomdplus.com and social media accounts, \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>https:\u002F\u002Ftwitter.com\u002FbioMDplus\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>, https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F and https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>From your website www.biomdplus.com:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, \"Best CBD Oil for Stress &amp; Depression: Can CBD Oil Help?\":\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Many are turning to consume CBD oil for anxiety, depression, and bipolar disorder.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The pre-clinical data support the possible use of CBD with Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), and Post Traumatic Stress Disorder (PTSD), and Bipolar Disorder.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “CBD for Psychosis vs CBD Oil for Schizophrenia: Breaking News…”: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“People are now taking CBD for anxiety, stress relief, proper pain medication, and to help fight addiction.” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“High-level CBD can help manage symptoms of psychosis that come from schizophrenia.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “CBD Oil Benefits”: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Relief for Chronic Pain . . . [t]hose who suffer from chronic pain from diseases such as fibromyalgia find relief in CBD. Taking CBD can relieve pain and even prevent the degeneration of the nervous system.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“IBD . . . [s]everal studies have suggested that one of the most important effects of CBD is that it may help patients with inflammatory bowel disease such as ulcerative colitis and Crohn’s disease.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “CBD Oil for Sundowning, Dementia, Alzheimer’s Disease &amp; Disorientation”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The dementia-related conditions that can be helped by CBD Oil include Alzheimer’s disease, Vascular Dementia, Dementia with Lewy bodies (DLB), Parkinson’s disease, Frontotemporal dementia and Huntington’s disease.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD could help remove dementia from brain cells.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “Delta-8 THC: Discover This New Cannabinoid from Cannabis”: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[D]elta-8-THC was administered to eight children being treated for hematologic cancers. The children were 3 to 13 years old . . . [t]hey all experienced vomiting because of the chemo . . . they received delta-8-THC with their chemotherapy treatments, every single child stopped vomiting during and after their chemo sessions!”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[D]elta-8-THC has also been used to relieve pain, ease anxiety”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “How Long Does It Take For Results Using CBD Oil To Take Affect With OCD?”: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD oil is an effective natural treatment for OCD.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “How To Take CBD Oil For Crohn’s Disease? Finding The Right Dosage”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The study suggests that cbd oil or a derivative of it could be a useful treatment for Crohn’s.” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your blog post titled, “Is CBD Oil Good For Idiopathic Pulmonary Fibrosis? The Ultimate Therapeutic Guide”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[T]here are numerous studies that suggest CBD oil has the potential to treat a wide variety of health issues and could be effective in treating IPF [idiopathic pulmonary fibrosis].”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your Delta 8 Gummies product webpage: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Another benefit that many people don’t know is that Cannabidiol can help with the growth and healing of damaged tissue, and it can also help reduce chronic pain and the likelihood of developing certain cancers, such as breast and prostate.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The benefits of Delta 8 are the following . . . Reduce depression . . . Reduce anxiety and panic attacks . . .”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your CBD Pain Relief Cream webpage: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“bioMDplus Pain Cream in 500mg strength is a new formulated pain relief topical cream that made for use on sore muscle areas and areas where there is pain. bioMDplus Pain Cream infused with the Quality Full Spectrum CBD. bioMDplus CBD Cream provides effective, fast and long-lasting pain relief.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Begin by rubbing small amounts of CBD cream to the affected area and wait for about an hour. You can increase the quantity depending on how fast it works. If the effects of the cream are slow to kick in, then its [\u003Ci>sic\u003C\u002Fi>] recommended to re-apply CBD cream after every 3-4 hours. . . . Using CBD cream is like using a moisturizing lotion, but making sure to apply the optimal dosage of CBD cream isn’t easy. Users have to determine the milligrams of CBD in the cream and decide whether it’s good enough for pain relief. CBD creams with low amounts of CBD will probably be less useful than those with higher concentrations. Begin by using small amounts of CBD cream before slowly increasing it until you find relief. Moreover, applying CBD cream on the body isn’t known to produce any significant side effects.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD creams work when directly applied to the skin, which makes them an excellent alternative to traditional creams when it comes to pain relief. . . . For the most part, the effects of CBD cream can be felt 15-20 minutes and can keep working for as long as 6 hours or more.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Applying CBD-infused creams is generally a straightforward process. Look for the areas of your body most affected by pain and discomfort, and apply small amounts of CBD cream around those areas for local treatment. . . . Elbows, knees, and joint . . . Bottoms of the feet and impact points . . . Face, particularly around the temples and the nose . . . Neck and shoulders” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>From your social media websites:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your Facebook Social Media page https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>July 28, 2020 post – “Recent research has linked CBD with several benefits for the heart and circulatory system, including the ability to lower high blood pressure. High blood pressure is linked to higher risks of a number of health conditions, including stroke, heart attack, and metabolic syndrome.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>April 14, 2020 post – “500mg: CBD &amp; Menthol Pain Cream . . . bioMDplus 500mg CBD Pain Cream is a newly formulated pain relief topical cream made to soothe sore muscles and alleviate chronic joint pain. Derived from our signature potent hemp oil infused with peppermint oil, eucalyptus oil, menthol and our signature terpene blend, this cream allows for a unique and STRONG combination of natural ingredients and CBD to aid in POWERFUL relief. You can use our new topical pain cream to FIGHT back against sore muscles and achy joints!”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>April 7, 2020 post – “Just what does CBD do for the body and why are people so interested in this substance? . . . Pain relief from arthritis or inflammatory diseases . . . Treatment of insomnia . . . Lowering anxiety levels . . . May lower diabetes risk . . . Could lower levels of obesity”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your Twitter Social Media Page \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>https:\u002F\u002Ftwitter.com\u002FbioMDplus\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>August 4, 2021 post – “62% of CBD users used it to treat health conditions. The most common uses were for pain, anxiety and depression.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>July 25, 2021 post – “CBD Oil for Depression, Anxiety, and Bipolar disorder.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your Instagram Social Media Page https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>July 4, 2020 post – “75% of PTSD patients saw a reduction in PTSD symptoms, when they were using CBD products compared to when they were not.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>November 5, 2019 post – “A recent study showed that CBD administration can prevent the death of the neurons and reduce brain damage in the event of a stroke. CBD also reduced stroke-related seizures.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Based on the above labeling claims, your CBD and Delta-8 THC products for human use are drugs. We are not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that any of these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended or suggested in their labeling. Thus, your CBD and Delta-8 THC products for human use are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>With certain exceptions not applicable here,\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca>\u003Csup>\u003Csup>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003C\u002Fsup>\u003C\u002Fa>\u003Cspan>\u003Cspan> new drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a), 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for your CBD and Delta-8 THC products for humans. There is no basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Misbranded Human Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> CBD and Delta-8 THC products for humans are also misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) These products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, because no FDA-approved applications are in effect \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>your products\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>.\u003Ca>\u003Csup>\u003Csup>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003C\u002Fsup>\u003C\u002Fa> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>CBD-containing Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Even if your “CBD Pain Relief Cream” was considered a nonprescription drug, we note that a nonprescription drug product containing CBD cannot be legally marketed without an approved new drug application, regardless of whether the CBD is represented on the labeling as an active ingredient or an inactive ingredient. To date, no CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use. Nonprescription drug products that include CBD as an active ingredient are not GRASE and are new drugs which require an approved application to be legally marketed. CBD is not an active ingredient in any OTC monograph under section 505G of the FD&amp;C Act. Even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed, because the product would not meet the general requirements under section 505G of the FD&amp;C Act under which certain nonprescription drug products may be marketed without an approved new drug application. In particular, such a product would not meet the general requirement with respect to the safety and suitability of inactive ingredients under 21 CFR 330.1(e).\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca>\u003Csup>\u003Csup>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003C\u002Fsup>\u003C\u002Fa>\u003Csup>\u003Cspan>\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Ca>\u003Cspan>\u003Cspan>[5]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Adulterated Human Foods\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>According to your product labeling, your “Delta 8 THC Gummies” product is a food to which Delta-8 THC has been added.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should be aware that, as defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[6]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Therefore, your “Delta 8 THC Gummies” are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive.&nbsp;Introduction of these adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>Unapproved New Animal Drugs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Based on our review of your website and social media websites, your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>“Natural Pet CBD Oil” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, this product is an unapproved new animal drug and marketing it violates the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Examples of claims from your website\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>https:\u002F\u002Fbiomdplus.com, and \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>your social media websites \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F, https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>, and https:\u002F\u002Ftwitter.com\u002Fbiomdplus, that provide evidence of the intended use of your “Natural Pet CBD Oil” as a drug include, but are not limited to, the following:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your product page for “\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Natural Pet CBD Oil”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Whether you’re using CBD oil for pain relief or anxiety, the right full spectrum CBD oil for dogs dosage depends on a number of factors. . . .”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“[L]inalool [an ingredient in your Natural Pet CBD Oil] may relieve . . . depression.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Humulene [an ingredient in your Natural Pet CBD Oil] . . . may help to reduce inflammation.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your webpage blog titled, “How Effective Is CBD For Pets?”: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“CBD tinctures are reported to help pets with seizures.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Thanks to the natural anti-in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>f\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>lammatory properties in CBD, it also makes for a great candidate in helping with anxiety, in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammation, and arthritis.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Under the heading “Top Uses CBD for Pets”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\n\t\u003Cul>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Anxiety[:] One of the major bene\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fi\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ts reported with CBD is that it can help . . . alleviate their anxiety. Most pets will suffer from varying degrees of anxiety, especially dogs and cats.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Pain . . . CBD can greatly help with [pain]. So any in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammatory pain that your pet may be suffering from may be greatly reduced with CBD. Since CBD has natural anti-in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammatory properties, it works especially well for in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammation-induced pain.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Arthritis[:] Although there are yet to be more tests on the effectiveness of CBD against arthritis, there is a substantial reason and some tests that prove its ef\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fi\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>cacy. Of course, the inherent anti-in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammatory properties of CBD do make it very valuable in providing substantial relief to arthritis. Moreover, research also supports these claims, ensuring that CBD can be a good substitute for regular arthritis medicine.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Seizures[:] Seizures among pets can be a very serious concern, but research suggests that CBD can help in reducing certain types of seizures in dogs. . . . In dogs, research conducted on idiopathic epilepsy showed that CBD assisted in reducing the intensity of seizures. So if your dog suffers from the condition, CBD can prove to be useful in bringing relief.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003C\u002Ful>\n\t\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your webpage blog titled, “Full Spectrum CBD Oil for Dogs”:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Here are a few problems full-spectrum CBD oil can help treat:” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\n\n\t\u003Cul>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Pain Including Joint Pain[:] It’s believed that CBD oil can reduce pain, especially neuropathic pain in dogs. It’s also said to be effective in reducing joint pain and arthritis, which is why it’s often recommended for older dogs.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Inflammation[:] CBD oil is anti-in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammatory and can help reduce chronic in\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fl\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ammation in dogs due to genetics, parasites, metabolic diseases, food allergies, bacterial \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>overgrowth, and environmental stress.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Anxiety[:] If your dog gets stressed or anxious then you may consider using CBD oil as it has been linked to less anxiety and stress.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>Digestion Problems . . . Regular use of full-spectrum CBD oil for dogs can treat this problem as it’s said to eliminate digestive issues”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Pain Symptoms[:] There are reasons to believe that the best full-spectrum CBD oil for dogs can help alleviate symptoms of pains in dogs. . . . The use of CBD oil may not cure the disease but it can help reduce the pain and suffering.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Seizures[:] Some experts are of the belief that regular use of full-spectrum CBD oil can reduce the risk of seizures in dogs. The AKC Canine Health Foundation is working with the Colorado State University to evaluate the use of full-spectrum CBD oil in treatment-resistant epileptic dogs. biomdplus offers the best full-spectrum CBD oil for dogs. Our product is meant to provide all the above-mentioned bene\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>fi\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>ts to dogs of all ages.”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003C\u002Ful>\n\t\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On both your Facebook and Instagram social media websites at https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F and\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F respectively:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Facebook and Instagram July 23, 2020 postings with a photograph of a cat looking at your “Natural Pet CBD Oil” product:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\n\n\t\u003Cul>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Use bioMD+ CBD products made for cats to help with . . . pain”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003C\u002Ful>\n\t\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Facebook and Instagram October 5, 2019 postings with a photograph of a dog licking a woman’s face:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\n\t\u003Cul>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“For pets who . . . have swollen joints, or separation anxiety CBD has helped many!”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003C\u002Ful>\n\t\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>On your Twitter social media website at \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>https:\u002F\u002Ftwitter.com\u002FbioMDplus\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>October 13, 2020 posting of a graphic titled “CBD FOR PETS . . . What can CBD do for your pet?” (checklist at the bottom next to clipboard titled “CONDITIONS TREATED”):\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\n\n\t\u003Cul>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>?\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan> Allergies”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Anxiety”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Cancer Management”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Inflamation \u003Ci>[sic]\u003C\u002Fi>”\u003Ci> \u003C\u002Fi>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Glaucoma” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Skin Irritation” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Seizures and Epilepsy”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cb>\u003Cspan>\u003Cspan>? \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fb>\u003Cspan>\u003Cspan>Arthritis”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003C\u002Ful>\n\t\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>“Natural Pet CBD Oil” product is a “new animal drug” under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. This product is not approved or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of this adulterated drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"mailto:FDAADVISORY@fda.hhs.gov\">\u003Cspan>\u003Cspan>FDAADVISORY@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Donald D. Ashley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Drug Evaluation and Research\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>Neal Bataller\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Division of Drug Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Surveillance &amp; Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Veterinary Medicine \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ann Oxenham\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Food Safety and Applied Nutrition\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> \u003Cspan>\u003Cspan>CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex.&nbsp;(See \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect.&nbsp; Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan> For example, under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, certain nonprescription drug products may be lawfully marketed without an approved application if applicable conditions are met, including conformity with an applicable OTC monograph. However, your products could not be lawfully marketed under section 505G, because based on your claims regarding these products, including on your website labeling, your products are marketed for uses not considered nonprescription indications.&nbsp; Further, even if certain of your products, such as your “CBD Pain Relief Cream” were marketed only for nonprescription indications, they would not meet the conditions under section 505G for lawful marketing without an approved application. For example, CBD — considered an active ingredient under 21 CFR 201.66(b)(2) due to its prominent featuring on your product labeling — is not an active ingredient in any OTC monograph under section 505G of the FD&amp;C Act. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> \u003Cspan>\u003Cspan>Further, even if your products were marketed only for nonprescription indications,\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>these products would be misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they would be nonprescription drugs subject to section 505G of the FD&amp;C Act that do not comply with the requirements for marketing under that section (see footnote 1) and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fspan>\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> \u003Cspan>\u003Cspan>21 CFR 330.1(e) requires in relevant part that \"the product contains only suitable inactive ingredients which are safe in the amounts administered.\" A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance). CBD has no known functional role as an inactive ingredient in a finished drug product. &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[5]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan> Additionally, an inactive ingredient should not exert pharmacological effects and must be safe when used at the intended dosage. CBD has known pharmacological activity with demonstrated risks. For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. It is unknown whether the levels of CBD used in your CBD products have pharmacological activity or pose any concern for safety events.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[6]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan> Under section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJonathan M. Levitt\n\nBioMD Plus LLC\n\n1371 Sheffield Pkwy\n\nMarietta, GA 30062\n\nUnited States\n\nsupport@biomdplus.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nMay 4, 2022\n\nRE: #618460\n\nDear Jonathan Levitt:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.biomdplus.com in February 2022 and has determined that you take orders there for various human and animal products, which you represent as containing cannabidiol (CBD) or Delta-8 tetrahydrocannabinol (THC). We have also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002FbioMDplus, https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F and https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F, which direct consumers to your website www.biomdplus.com to purchase your products. The claims on your website and social media accounts establish that your products, some of which are available in multiple varieties, “CBD Oil,” “CBD Capsules,” “Vegan CBD Gummies,” “CBD Pain Relief Cream,” “Delta 8 THC Gummies,” and “Delta 8 THC Vape Cartridge” (hereinafter referred to as “your CBD and Delta-8 THC products for humans”) are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1).\n\nIn addition, your “Natural Pet CBD Oil” is an unapproved new animal drug that is unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and is adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).\n\nFDA has also determined that certain food products that you market are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive.\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nOver the past several years, FDA has warned the public on various illegally marketed CBD-containing products. FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products, and Delta-8 THC may pose a serious health risk to consumers.\n\nDietary Supplement Labeling\n\nInformation on your website at www.biomdplus.com indicates that you appear to market your CBD-containing “CBD Capsules” and “Vegan CBD Gummies” as dietary supplements. For example, the product webpages display a product label image with “hemp supplement” on them. However, your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act, 21 U.S.C. 321(ff). FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii). Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.[1] There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.\n\nUnapproved New Human Drugs\n\nBased on a review of your website and social media accounts, your CBD and Delta-8 THC products for humans are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your website www.biomdplus.com and social media accounts, https:\u002F\u002Ftwitter.com\u002FbioMDplus, https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F and https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nFrom your website www.biomdplus.com:\n\nOn your blog post titled, \"Best CBD Oil for Stress & Depression: Can CBD Oil Help?\":\n\n“Many are turning to consume CBD oil for anxiety, depression, and bipolar disorder.”\n\n“The pre-clinical data support the possible use of CBD with Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), and Post Traumatic Stress Disorder (PTSD), and Bipolar Disorder.”\n\nOn your blog post titled, “CBD for Psychosis vs CBD Oil for Schizophrenia: Breaking News…”:\n\n“People are now taking CBD for anxiety, stress relief, proper pain medication, and to help fight addiction.”\n\n“High-level CBD can help manage symptoms of psychosis that come from schizophrenia.”\n\nOn your blog post titled, “CBD Oil Benefits”:\n\n“Relief for Chronic Pain . . . [t]hose who suffer from chronic pain from diseases such as fibromyalgia find relief in CBD. Taking CBD can relieve pain and even prevent the degeneration of the nervous system.”\n\n“IBD . . . [s]everal studies have suggested that one of the most important effects of CBD is that it may help patients with inflammatory bowel disease such as ulcerative colitis and Crohn’s disease.”\n\nOn your blog post titled, “CBD Oil for Sundowning, Dementia, Alzheimer’s Disease & Disorientation”:\n\n“The dementia-related conditions that can be helped by CBD Oil include Alzheimer’s disease, Vascular Dementia, Dementia with Lewy bodies (DLB), Parkinson’s disease, Frontotemporal dementia and Huntington’s disease.”\n\n“CBD could help remove dementia from brain cells.”\n\nOn your blog post titled, “Delta-8 THC: Discover This New Cannabinoid from Cannabis”:\n\n“[D]elta-8-THC was administered to eight children being treated for hematologic cancers. The children were 3 to 13 years old . . . [t]hey all experienced vomiting because of the chemo . . . they received delta-8-THC with their chemotherapy treatments, every single child stopped vomiting during and after their chemo sessions!”\n\n“[D]elta-8-THC has also been used to relieve pain, ease anxiety”\n\nOn your blog post titled, “How Long Does It Take For Results Using CBD Oil To Take Affect With OCD?”:\n\n“CBD oil is an effective natural treatment for OCD.”\n\nOn your blog post titled, “How To Take CBD Oil For Crohn’s Disease? Finding The Right Dosage”:\n\n“The study suggests that cbd oil or a derivative of it could be a useful treatment for Crohn’s.”\n\nOn your blog post titled, “Is CBD Oil Good For Idiopathic Pulmonary Fibrosis? The Ultimate Therapeutic Guide”:\n\n“[T]here are numerous studies that suggest CBD oil has the potential to treat a wide variety of health issues and could be effective in treating IPF [idiopathic pulmonary fibrosis].”\n\nOn your Delta 8 Gummies product webpage:\n\n“Another benefit that many people don’t know is that Cannabidiol can help with the growth and healing of damaged tissue, and it can also help reduce chronic pain and the likelihood of developing certain cancers, such as breast and prostate.”\n\n“The benefits of Delta 8 are the following . . . Reduce depression . . . Reduce anxiety and panic attacks . . .”\n\nOn your CBD Pain Relief Cream webpage:\n\n“bioMDplus Pain Cream in 500mg strength is a new formulated pain relief topical cream that made for use on sore muscle areas and areas where there is pain. bioMDplus Pain Cream infused with the Quality Full Spectrum CBD. bioMDplus CBD Cream provides effective, fast and long-lasting pain relief.”\n\n“Begin by rubbing small amounts of CBD cream to the affected area and wait for about an hour. You can increase the quantity depending on how fast it works. If the effects of the cream are slow to kick in, then its [sic] recommended to re-apply CBD cream after every 3-4 hours. . . . Using CBD cream is like using a moisturizing lotion, but making sure to apply the optimal dosage of CBD cream isn’t easy. Users have to determine the milligrams of CBD in the cream and decide whether it’s good enough for pain relief. CBD creams with low amounts of CBD will probably be less useful than those with higher concentrations. Begin by using small amounts of CBD cream before slowly increasing it until you find relief. Moreover, applying CBD cream on the body isn’t known to produce any significant side effects.”\n\n“CBD creams work when directly applied to the skin, which makes them an excellent alternative to traditional creams when it comes to pain relief. . . . For the most part, the effects of CBD cream can be felt 15-20 minutes and can keep working for as long as 6 hours or more.”\n\n“Applying CBD-infused creams is generally a straightforward process. Look for the areas of your body most affected by pain and discomfort, and apply small amounts of CBD cream around those areas for local treatment. . . . Elbows, knees, and joint . . . Bottoms of the feet and impact points . . . Face, particularly around the temples and the nose . . . Neck and shoulders”\n\nFrom your social media websites:\n\nOn your Facebook Social Media page https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F:\n\nJuly 28, 2020 post – “Recent research has linked CBD with several benefits for the heart and circulatory system, including the ability to lower high blood pressure. High blood pressure is linked to higher risks of a number of health conditions, including stroke, heart attack, and metabolic syndrome.”\n\nApril 14, 2020 post – “500mg: CBD & Menthol Pain Cream . . . bioMDplus 500mg CBD Pain Cream is a newly formulated pain relief topical cream made to soothe sore muscles and alleviate chronic joint pain. Derived from our signature potent hemp oil infused with peppermint oil, eucalyptus oil, menthol and our signature terpene blend, this cream allows for a unique and STRONG combination of natural ingredients and CBD to aid in POWERFUL relief. You can use our new topical pain cream to FIGHT back against sore muscles and achy joints!”\n\nApril 7, 2020 post – “Just what does CBD do for the body and why are people so interested in this substance? . . . Pain relief from arthritis or inflammatory diseases . . . Treatment of insomnia . . . Lowering anxiety levels . . . May lower diabetes risk . . . Could lower levels of obesity”\n\nOn your Twitter Social Media Page https:\u002F\u002Ftwitter.com\u002FbioMDplus:\n\nAugust 4, 2021 post – “62% of CBD users used it to treat health conditions. The most common uses were for pain, anxiety and depression.”\n\nJuly 25, 2021 post – “CBD Oil for Depression, Anxiety, and Bipolar disorder.”\n\nOn your Instagram Social Media Page https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F:\n\nJuly 4, 2020 post – “75% of PTSD patients saw a reduction in PTSD symptoms, when they were using CBD products compared to when they were not.”\n\nNovember 5, 2019 post – “A recent study showed that CBD administration can prevent the death of the neurons and reduce brain damage in the event of a stroke. CBD also reduced stroke-related seizures.”\n\nBased on the above labeling claims, your CBD and Delta-8 THC products for human use are drugs. We are not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that any of these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended or suggested in their labeling. Thus, your CBD and Delta-8 THC products for human use are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here,[2] new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a), 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for your CBD and Delta-8 THC products for humans. There is no basis under the FD&C Act under which these products would be legally marketed without an approved application. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nMisbranded Human Drugs\n\nYour CBD and Delta-8 THC products for humans are also misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) These products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, because no FDA-approved applications are in effect your products.[3]\n\nThe introduction or delivery for introduction into interstate commerce of misbranded drugs is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCBD-containing Drugs\n\nEven if your “CBD Pain Relief Cream” was considered a nonprescription drug, we note that a nonprescription drug product containing CBD cannot be legally marketed without an approved new drug application, regardless of whether the CBD is represented on the labeling as an active ingredient or an inactive ingredient. To date, no CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use. Nonprescription drug products that include CBD as an active ingredient are not GRASE and are new drugs which require an approved application to be legally marketed. CBD is not an active ingredient in any OTC monograph under section 505G of the FD&C Act. Even if CBD could be considered an inactive ingredient in a nonprescription drug product, that product would still need an approved new drug application to be legally marketed, because the product would not meet the general requirements under section 505G of the FD&C Act under which certain nonprescription drug products may be marketed without an approved new drug application. In particular, such a product would not meet the general requirement with respect to the safety and suitability of inactive ingredients under 21 CFR 330.1(e).[4], [5]\n\nAdulterated Human Foods\n\nAccording to your product labeling, your “Delta 8 THC Gummies” product is a food to which Delta-8 THC has been added.\n\nYou should be aware that, as defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.[6]\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your “Delta 8 THC Gummies” are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nUnapproved New Animal Drugs\n\nBased on our review of your website and social media websites, your “Natural Pet CBD Oil” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, this product is an unapproved new animal drug and marketing it violates the FD&C Act.\n\nExamples of claims from your website https:\u002F\u002Fbiomdplus.com, and your social media websites https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F, https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F, and https:\u002F\u002Ftwitter.com\u002Fbiomdplus, that provide evidence of the intended use of your “Natural Pet CBD Oil” as a drug include, but are not limited to, the following:\n\nOn your product page for “Natural Pet CBD Oil”:\n\n“Whether you’re using CBD oil for pain relief or anxiety, the right full spectrum CBD oil for dogs dosage depends on a number of factors. . . .”\n\n“[L]inalool [an ingredient in your Natural Pet CBD Oil] may relieve . . . depression.”\n\n“Humulene [an ingredient in your Natural Pet CBD Oil] . . . may help to reduce inflammation.”\n\nOn your webpage blog titled, “How Effective Is CBD For Pets?”:\n\n“CBD tinctures are reported to help pets with seizures.”\n\n“Thanks to the natural anti-inflammatory properties in CBD, it also makes for a great candidate in helping with anxiety, inflammation, and arthritis.”\n\nUnder the heading “Top Uses CBD for Pets”:\n\n“Anxiety[:] One of the major benefits reported with CBD is that it can help . . . alleviate their anxiety. Most pets will suffer from varying degrees of anxiety, especially dogs and cats.”\n\n“Pain . . . CBD can greatly help with [pain]. So any inflammatory pain that your pet may be suffering from may be greatly reduced with CBD. Since CBD has natural anti-inflammatory properties, it works especially well for inflammation-induced pain.”\n\n“Arthritis[:] Although there are yet to be more tests on the effectiveness of CBD against arthritis, there is a substantial reason and some tests that prove its efficacy. Of course, the inherent anti-inflammatory properties of CBD do make it very valuable in providing substantial relief to arthritis. Moreover, research also supports these claims, ensuring that CBD can be a good substitute for regular arthritis medicine.”\n\n“Seizures[:] Seizures among pets can be a very serious concern, but research suggests that CBD can help in reducing certain types of seizures in dogs. . . . In dogs, research conducted on idiopathic epilepsy showed that CBD assisted in reducing the intensity of seizures. So if your dog suffers from the condition, CBD can prove to be useful in bringing relief.”\n\nOn your webpage blog titled, “Full Spectrum CBD Oil for Dogs”:\n\n“Here are a few problems full-spectrum CBD oil can help treat:”\n\n“Pain Including Joint Pain[:] It’s believed that CBD oil can reduce pain, especially neuropathic pain in dogs. It’s also said to be effective in reducing joint pain and arthritis, which is why it’s often recommended for older dogs.”\n\n“Inflammation[:] CBD oil is anti-inflammatory and can help reduce chronic inflammation in dogs due to genetics, parasites, metabolic diseases, food allergies, bacterial overgrowth, and environmental stress.”\n\n“Anxiety[:] If your dog gets stressed or anxious then you may consider using CBD oil as it has been linked to less anxiety and stress.”\n\n“Digestion Problems . . . Regular use of full-spectrum CBD oil for dogs can treat this problem as it’s said to eliminate digestive issues”\n\n“Pain Symptoms[:] There are reasons to believe that the best full-spectrum CBD oil for dogs can help alleviate symptoms of pains in dogs. . . . The use of CBD oil may not cure the disease but it can help reduce the pain and suffering.”\n\n“Seizures[:] Some experts are of the belief that regular use of full-spectrum CBD oil can reduce the risk of seizures in dogs. The AKC Canine Health Foundation is working with the Colorado State University to evaluate the use of full-spectrum CBD oil in treatment-resistant epileptic dogs. biomdplus offers the best full-spectrum CBD oil for dogs. Our product is meant to provide all the above-mentioned benefits to dogs of all ages.”\n\nOn both your Facebook and Instagram social media websites at https:\u002F\u002Fwww.facebook.com\u002FbioMDplus\u002F and https:\u002F\u002Fwww.instagram.com\u002Fbiomdplus\u002F respectively:\n\nFacebook and Instagram July 23, 2020 postings with a photograph of a cat looking at your “Natural Pet CBD Oil” product:\n\n“Use bioMD+ CBD products made for cats to help with . . . pain”\n\nFacebook and Instagram October 5, 2019 postings with a photograph of a dog licking a woman’s face:\n\n“For pets who . . . have swollen joints, or separation anxiety CBD has helped many!”\n\nOn your Twitter social media website at https:\u002F\u002Ftwitter.com\u002FbioMDplus:\n\nOctober 13, 2020 posting of a graphic titled “CBD FOR PETS . . . What can CBD do for your pet?” (checklist at the bottom next to clipboard titled “CONDITIONS TREATED”):\n\n“? Allergies”\n\n“? Anxiety”\n\n“? Cancer Management”\n\n“? Inflamation [sic]”\n\n“? Glaucoma”\n\n“? Skin Irritation”\n\n“? Seizures and Epilepsy”\n\n“? Arthritis”\n\nYour “Natural Pet CBD Oil” product is a “new animal drug” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\n\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. This product is not approved or index listed by the FDA, and therefore this product is considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of this adulterated drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nNeal Bataller\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nAnn Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n[1] CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n[2] For example, under section 505G of the FD&C Act, 21 U.S.C. 355h, certain nonprescription drug products may be lawfully marketed without an approved application if applicable conditions are met, including conformity with an applicable OTC monograph. However, your products could not be lawfully marketed under section 505G, because based on your claims regarding these products, including on your website labeling, your products are marketed for uses not considered nonprescription indications. Further, even if certain of your products, such as your “CBD Pain Relief Cream” were marketed only for nonprescription indications, they would not meet the conditions under section 505G for lawful marketing without an approved application. For example, CBD — considered an active ingredient under 21 CFR 201.66(b)(2) due to its prominent featuring on your product labeling — is not an active ingredient in any OTC monograph under section 505G of the FD&C Act.\n\n[3] Further, even if your products were marketed only for nonprescription indications, these products would be misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they would be nonprescription drugs subject to section 505G of the FD&C Act that do not comply with the requirements for marketing under that section (see footnote 1) and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\n[4] 21 CFR 330.1(e) requires in relevant part that \"the product contains only suitable inactive ingredients which are safe in the amounts administered.\" A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance). CBD has no known functional role as an inactive ingredient in a finished drug product.\n\n[5] Additionally, an inactive ingredient should not exert pharmacological effects and must be safe when used at the intended dosage. CBD has known pharmacological activity with demonstrated risks. For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf. It is unknown whether the levels of CBD used in your CBD products have pharmacological activity or pose any concern for safety events.\n\n[6] Under section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.","BioMD Plus LLC","biomd-plus-llc-618460-05042022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomd-plus-llc-618460-05042022","2026-10-26T08:08:05.09658+00:00","2022-05-04","618460","Animal & VeterinaryDrugsFood & Beverages","Jonathan M. Levitt","2026-08-20T01:56:23.698+00:00","Via Email",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":70,"body_fetched_at":71,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},534,[56,57,58,11,59,13,13,13],"\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-09T04:00:00Z\">10\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmelcare-biomedical-pty-ltd-717968-10092025\">Melcare Biomedical Pty Ltd\u003C\u002Fa>","Nonprescription\u002FOTC\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthony Moloney\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Melcare Biomedical Pty Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>451 West Mount Cotton Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Cotton\u003C\u002Fspan> \u003Cspan>QLD\u003C\u002Fspan> \u003Cspan>4165\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Australia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:anthonym@melcare.com\"> anthonym@melcare.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 9, 2025\u003C\u002Fp>\u003Cp>RE: 717968\u003C\u002Fp>\u003Cp>Dear Mr. Moloney:\u003C\u002Fp>\u003Cp>This letter is to advise you that on September 10, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address melcare.com where your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are available for purchase in the United States without a prescription. We also reviewed your social media site on YouTube https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&amp;t=12s, which is listed on your website.\u003C\u002Fp>\u003Cp>Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims from the Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops labeling, including on your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Optimel Manuka+ Forte Eye Gel\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“DRUG FACTS…USES…▪for the temporary relief of irritation due to dryness of the eye. ▪ for use as a protectant against further irritation or to relive dryness of the eye.” [from the Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>“Suitable For: ▪Aqueous tear deficiency ▪ eye discomfort ▪ eye lid irritation [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\u003C\u002Fp>\u003Cp>“Melcare’s Optimel Manuka+ Forte Eye Gel contains a standardised [sic] medical grade Manuka honey developed from \u003Cem>Leptospermum\u003C\u002Fem> spp. and is preservative free for moderate to severe dry eye” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\u003C\u002Fp>\u003Cp>“Albietz and Lenton also reported that the application of medical grade \u003Cem>Leptospermum\u003C\u002Fem> spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\u003C\u002Fp>\u003Cp>“Indications…Optimel Manuka+ Forte Eye Gel containing 98% honey with increased viscosity is preservative free, and is also available for more difficult conditions from your eye care specialist.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Optimel Manuka+ Dry Eye Drops\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“DRUG FACTS…USES… ▪for the temporary relief of irritation due to the dryness of the eye. ▪ for use as a protectant against further irritation or to relieve dryness of the eye.” [from the Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>“Suitable For: ▪Chronic dry eye ▪ Eye discomfort ▪ Sore, irritated eyes and eyelids” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\u003C\u002Fp>\u003Cp>“About the Product…Albietz and Lenton also reported that the application of medical grade \u003Cem>Leptospermum\u003C\u002Fem> spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Multiple products\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“At Melcare, we are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease. Honeys from Australian and New Zealand \u003Cem>Leptospermum\u003C\u002Fem> spp, commonly called Manuka, a small native tree is favoured because of its well-studied composition and antibacterial activity.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fabout-us\u002F]\u003C\u002Fp>\u003Cp>YouTube video posted on your website created on June 18, 2020 that includes statements by Melcare’s President, Anthony Maloney, emphasizes the use of honey and it’s benefits in drug products. For example, Mr. Maloney states in the video, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” [from your YouTube video on your product website at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&amp;t=12s]\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are intended for use as ophthalmic demulcent (lubricant) drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for any of the product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops, in order to be GRASE and not new drugs, these products must, among other things, conform to the conditions in the applicable OTC monograph, here OTC monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not conform to the conditions specified in M018 for the reasons described below, and thus cannot be legally marketed under section 505G.\u003C\u002Fp>\u003Cp>Specifically, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are formulated with honey (from \u003Cem>Leptospermum\u003C\u002Fem> spp.). Although you identify honey as an inactive ingredient on the product label, statements on your website show that honey is presented as an active ingredient, because it is intended to furnish pharmacological activity for the treatment of a disease or condition.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, honey is not an active ingredient permitted for OTC monograph ophthalmic demulcent drug products under M018.12. Examples of you labeling statements presenting honey as an active ingredient include, “Optimel Manuka+ Forte Eye Gel contains a standardised medical grade Manuka honey developed from \u003Cem>Leptospermum\u003C\u002Fem> spp. and is preservative free for moderate to severe dry eye,” “The application of medical grade \u003Cem>Leptospermum\u003C\u002Fem> spp honey (Manuka) was associated with significant clinical improvements in dry eye and meibomian gland dysfunction,” and “We are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease.” Additionally, a YouTube video created on June 18, 2020 and posted on your website includes statements by Melcare’s President, Anthony Maloney, describing the medical benefits of honey. For example, Mr. Maloney states, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” Thus, honey is used in your product as an active ingredient and, because it is not an active ingredient permitted under M018.12, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products do not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent or vasoconstrictor drug product as set forth in M018.\u003C\u002Fp>\u003Cp>Therefore, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not comply with the applicable conditions specified in M018. In addition, these products have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov . Please include your firm name and the unique identifier 717968 in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3 \u003C\u002Fstrong>\u003C\u002Fem>FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nAnthony Moloney\n\nRecipient Title\n\nGroup CEO\n\nMelcare Biomedical Pty Ltd\n\n451 West Mount Cotton Rd\n\nMount Cotton QLD 4165\n\nAustralia\n\nanthonym@melcare.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nOctober 9, 2025\nRE: 717968\nDear Mr. Moloney:\nThis letter is to advise you that on September 10, 2025 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address melcare.com where your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are available for purchase in the United States without a prescription. We also reviewed your social media site on YouTube https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&t=12s, which is listed on your website.\nOptimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nOptimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples of claims from the Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops labeling, including on your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nOptimel Manuka+ Forte Eye Gel\n“DRUG FACTS…USES…▪for the temporary relief of irritation due to dryness of the eye. ▪ for use as a protectant against further irritation or to relive dryness of the eye.” [from the Drug Facts panel on product carton labeling]\n“Suitable For: ▪Aqueous tear deficiency ▪ eye discomfort ▪ eye lid irritation [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\n“Melcare’s Optimel Manuka+ Forte Eye Gel contains a standardised [sic] medical grade Manuka honey developed from Leptospermum spp. and is preservative free for moderate to severe dry eye” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\n“Albietz and Lenton also reported that the application of medical grade Leptospermum spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-manuka-forte-eye-gel\u002F]\n“Indications…Optimel Manuka+ Forte Eye Gel containing 98% honey with increased viscosity is preservative free, and is also available for more difficult conditions from your eye care specialist.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\nOptimel Manuka+ Dry Eye Drops\n“DRUG FACTS…USES… ▪for the temporary relief of irritation due to the dryness of the eye. ▪ for use as a protectant against further irritation or to relieve dryness of the eye.” [from the Drug Facts panel on product carton labeling]\n“Suitable For: ▪Chronic dry eye ▪ Eye discomfort ▪ Sore, irritated eyes and eyelids” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\n“About the Product…Albietz and Lenton also reported that the application of medical grade Leptospermum spp honey (Manuka) was associated with signficant [sic] clinical improvements in dry eye and meibomian gland dysfunction.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fproduct\u002Foptimel-dry-eye-drops\u002F]\nMultiple products\n“At Melcare, we are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease. Honeys from Australian and New Zealand Leptospermum spp, commonly called Manuka, a small native tree is favoured because of its well-studied composition and antibacterial activity.” [from your product website at https:\u002F\u002Fmelcare.com\u002Fabout-us\u002F]\nYouTube video posted on your website created on June 18, 2020 that includes statements by Melcare’s President, Anthony Maloney, emphasizes the use of honey and it’s benefits in drug products. For example, Mr. Maloney states in the video, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” [from your YouTube video on your product website at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=W0nofWh_uGU&t=12s]\nUnapproved New Drug Violations\nBased on the above labeling evidence, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are intended for use as ophthalmic demulcent (lubricant) drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for any of the product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops, in order to be GRASE and not new drugs, these products must, among other things, conform to the conditions in the applicable OTC monograph, here OTC monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).1 However, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not conform to the conditions specified in M018 for the reasons described below, and thus cannot be legally marketed under section 505G.\nSpecifically, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are formulated with honey (from Leptospermum spp.). Although you identify honey as an inactive ingredient on the product label, statements on your website show that honey is presented as an active ingredient, because it is intended to furnish pharmacological activity for the treatment of a disease or condition.2 However, honey is not an active ingredient permitted for OTC monograph ophthalmic demulcent drug products under M018.12. Examples of you labeling statements presenting honey as an active ingredient include, “Optimel Manuka+ Forte Eye Gel contains a standardised medical grade Manuka honey developed from Leptospermum spp. and is preservative free for moderate to severe dry eye,” “The application of medical grade Leptospermum spp honey (Manuka) was associated with significant clinical improvements in dry eye and meibomian gland dysfunction,” and “We are experts in the therapeutic use of honey in products to help relieve some of the symptoms associated with chronic disease.” Additionally, a YouTube video created on June 18, 2020 and posted on your website includes statements by Melcare’s President, Anthony Maloney, describing the medical benefits of honey. For example, Mr. Maloney states, “We developed a range of products that use and leverage off the therapeutic efficacy of honey that is in wound care, eye care, skin care, and throat care.” Thus, honey is used in your product as an active ingredient and, because it is not an active ingredient permitted under M018.12, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products do not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent or vasoconstrictor drug product as set forth in M018.\nTherefore, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops drug products do not comply with the applicable conditions specified in M018. In addition, these products have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, your Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov . Please include your firm name and the unique identifier 717968 in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nCc: (b)(4)\n__________________\n1 M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n2 See21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that Optimel Manuka+ Forte Eye Gel and Optimel Manuka+ Dry Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","Melcare Biomedical Pty Ltd","melcare-biomedical-pty-ltd-717968-10092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmelcare-biomedical-pty-ltd-717968-10092025","2026-10-26T08:09:23.825007+00:00","2025-10-21","717968","Anthony Moloney","2026-08-19T16:13:40.714+00:00","2025-10-09",{"id":74,"raw":75,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":44,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},2638,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2022-05-31T13:20:00Z\">05\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-31T04:00:00Z\">03\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fosteolife-biomedical-i-llc-626889-03312022\">OsteoLife Biomedical I LLC\u003C\u002Fa>","Office of Biological Products Operations – Division I","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Theodore I. Malinin, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Medical Director and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OsteoLife Biomedical I LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1951 NW 7th Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanibel Suite\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33136\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 31, 2022\u003C\u002Fp>\n\n\u003Cp>22-626889\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Malinin:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, OsteoLife Biomedical I LLC, located at 1951 NW 7th Avenue, Sanibel Suite, Miami, FL, between December 6, 2021 and February 4, 2022. During the inspection, an FDA investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations (Form FDA-483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1) Failure to process HCT\u002FPs in a way that does not cause contamination or cross-contamination during processing and that prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP [21 CFR 1271.220(a)]. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your establishment processes multiple batches of Freeze-Dried Particulate Bone from a single donor on the same day, by the same processing technician, under the same environmental conditions, and using the same equipment. Cleaning of equipment and facilities is not performed in \u003Cstrong>(b)(4)\u003C\u002Fstrong> each batch. Post-processing cultures of vials from one or more batches from a single donor tested positive for microorganisms, several of which were identified on multiple occasions. Although positive microbiological cultures were found in some batches, other batches from the same donor were distributed. For example:\u003C\u002Fp>\n\n\u003Cp>i. On November 16, 2021, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. A post-processing culture was positive for \u003Cem>Bacillus\u003C\u002Fem> (not \u003Cem>anthracis\u003C\u002Fem>) in one batch manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>ii. On July 7, 2021, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. Post-processing cultures were positive for \u003Cem>Stenotrophomonas maltophilia\u003C\u002Fem> in two batches manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>iii. On May 13, 2021, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. Post-processing cultures were positive for \u003Cem>Stenotrophomonas maltophilia\u003C\u002Fem> or \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> in four batches manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>iv. On April 30, 2020, \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of Freeze-Dried Particulate Bone were manufactured from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong>. A post-processing culture was positive for \u003Cem>Micrococcus luteus\u003C\u002Fem> in one batch manufactured from this donor.\u003C\u002Fp>\n\n\u003Cp>b. During the inspection, the FDA investigator observed processing of HCT\u002FPs, from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on December 28, 2021, that significantly increased the potential for contamination and did not prevent the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FPs. Specifically, the investigator noted the high velocity return air slots of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Laminar Flow Bench, located along the front edge of the work surface and that provide protection from a “backwash” of dirty air into the work area, were covered with a sterile sheet\u002Fdrape.\u003C\u002Fp>\n\n\u003Cp>2) Failure to validate and approve processes according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests [21 CFR 1271.230(a)]. For example:\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate the manufacturing process for the Flexo-Plate, and Flexo-Membrane, and Freeze-Dried Particulate Bone products. Your “Processing of Flexo-plate and Membrane Grafts Process Qualification Summary Report” (dated October 14, 2019) and “Processing of Particulate Tissue Process Qualification Summary Report” (dated October 4, 2019) fail to include in-process microbiological testing to ensure that you are not introducing contamination during processing and that your process removes any contamination present. In addition, the documents noted above do not include any acceptance criteria related to microbiological contamination of HCT\u002FPs or the types of microorganisms typically encountered on such HCT\u002FPs.\u003C\u002Fp>\n\n\u003Cp>3) Failure to monitor environmental conditions where they could reasonably be expected to cause contamination or cross contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example:\u003C\u002Fp>\n\n\u003Cp>Your January 2020 through November 2021 processing session logs indicate that you conduct environmental monitoring for microorganisms approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you do not perform environmental monitoring during processing. The introduction, transmission, or spread of communicable diseases could reasonably be expected to occur during processing, therefore, you would be expected to perform environmental monitoring for microorganisms during processing.\u003C\u002Fp>\n\n\u003Cp>4) Failure to investigate HCT\u002FP deviations and trends of HCT\u002FP deviations relating to core CGTP requirements. Under the applicable regulation, each investigation must include a review and evaluation of the HCT\u002FP deviation, the efforts made to determine the cause, and the implementation of corrective action(s) to address the HCT\u002FP deviation and prevent recurrence [21 CFR 1271.160(b)(6)]. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. After the issuance of an Untitled Letter dated July 22, 2019, you submitted an initial HCT\u002FP deviation report to FDA on September 17, 2019, regarding the distribution of HCT\u002FPs after receipt of positive post-processing cultures. You submitted supplemental information on November 1, 2019, and April 14, 2020. The deviation reports stated you performed an investigation and proposed the reason for the positive post-processing cultures as inadvertent contamination of the sample at the microbiology laboratory when the plastic pouch containing the sample was opened by the testing laboratory that performed the microbiological testing.\u003C\u002Fp>\n\n\u003Cp>As noted above, you continued to have positive post-processing cultures. You subsequently opened 22 investigations of positive post-processing cultures for bone products processed between April 2020 and December 2021; however, the investigations were closed and once again, you failed to identify corrective actions to address the ongoing deviations and to prevent their recurrence. For example:\u003C\u002Fp>\n\n\u003Cp>i. On May 24, 2021, post-processing cultures for Freeze-Dried Particulate Bone from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> tested positive for \u003Cem>Stenotrophomonas maltophilia\u003C\u002Fem> and \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem>. You opened “HCT\u002FP Deviation #005” after the initiation of the inspection and closed the investigation on December 7, 2021.\u003C\u002Fp>\n\n\u003Cp>ii. On May 8, 2020, post-processing cultures for Freeze-Dried Particulate Bone from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> tested positive for \u003Cem>Micrococcus luteus\u003C\u002Fem>. You opened “HCT\u002FP Deviation #001” after the initiation of the inspection and closed the investigation on December 7, 2021.\u003C\u002Fp>\n\n\u003Cp>b. Between January 2020 and November 2021, you performed environmental monitoring prior to cleaning your processing room, which resulted in 10 positive microbiological cultures from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, one positive microbiological culture from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for multiple processing steps to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and one positive microbiological culture from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Laminar Flow Bench. For example:\u003C\u002Fp>\n\n\u003Cp>i. On July 29, 2021, an environmental settling plate (S-072221-09235) from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> table tested positive for Fungi, and \u003Cem>Bacillus\u003C\u002Fem> species (not \u003Cem>anthracis\u003C\u002Fem>). You opened “HCT\u002FP Deviation #E002” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>ii. On July 12, 2021, an environmental settling plate (S-070421-03649) from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Laminar Flow Bench tested positive for gram-positive cocci and \u003Cem>Staphylococcus petrasii\u003C\u002Fem>. You opened “HCT\u002FP Deviation #E001” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>iii. On September 8, 2020, an environmental touch plate (S-090220-08144) from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tested positive for \u003Cem>Bacillus\u003C\u002Fem> species (not \u003Cem>anthracis\u003C\u002Fem>), coagulase-negative \u003Cem>Staphylococcus\u003C\u002Fem>, and \u003Cem>Bacillus marisflavi\u003C\u002Fem>. You opened “HCT\u002FP Deviation #E-006” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure that your establishment is operating in compliance with all the applicable regulatory requirements. You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letter dated February 23, 2022, in response to the Form FDA-483, issued to your establishment at the close of the inspection. We have reviewed the corrective actions outlined in the response and we have the following comments:\u003C\u002Fp>\n\n\u003Cp>1. In your response to Observation 1, under paragraph 1(a), your revised SOP 110-006, Release of Processed Tissues states, “... in the event of a positive culture(s) the entire number of batches processed from the same donor during a processing session will be discarded.” Your response does not address your plan for the HCT\u002FPs you have already processed in violation of 21 CFR 1271 that have already been distributed, as well as the HCT\u002FPs that currently remain in storage.\u003C\u002Fp>\n\n\u003Cp>2. In response to Observation 2, under paragraph 2(b) you stated you would, “Revalidate entire process for Processing of Flexo-Plate &amp; Flexo-Membrane Grafts and Particulate Tissue.” We note that under 21 CFR 1271.230(a), process validation must be performed before manufacturing HCT\u002FPs. Your response does not indicate that you will halt processing of Flexo-Plate &amp; Flexo-Membrane Grafts and Particulate Tissue products until your processes have been validated.\u003C\u002Fp>\n\n\u003Cp>3. In response to Observations 4 and 5, you stated that “CAPA#002, Manufacturing monitoring to mitigate contamination” and “CAPA#003, Environmental monitoring” were initiated as corrective actions and that they would be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\u003C\u002Fp>\n\n\u003Cp>4. In response to Observation 6, you stated that CAPA #001, “Quality Program Continuous Improvement and Enforcement” was initiated that includes drafting a new SOP on how to perform investigations detailing root cause analysis to be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Given the seriousness of these violations, we also request your attendance at a Regulatory Meeting, within 30 calendar days of receipt of this letter, to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. We will host the meeting virtually on Zoom. This meeting will also allow you to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or by email at Colleen.Aspinwall@fda.hhs.gov for confirmation of the meeting date and time. A call-in phone number for the Zoom meeting will be provided at that time.\u003C\u002Fp>\n\n\u003Cp>Your response should be emailed to Colleen.Aspinwall@fda.hhs.gov. If you should have any questions, please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or via email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division I\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nTheodore I. Malinin, MD\n\nRecipient Title\n\nMedical Director and Co-Owner\n\nOsteoLife Biomedical I LLC\n\n1951 NW 7th Avenue\n\nSanibel Suite\n\nMiami, FL 33136\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division I\n\nUnited States\n\nWARNING LETTER\n\nMarch 31, 2022\n\n22-626889\n\nDear Dr. Malinin:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, OsteoLife Biomedical I LLC, located at 1951 NW 7th Avenue, Sanibel Suite, Miami, FL, between December 6, 2021 and February 4, 2022. During the inspection, an FDA investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations (Form FDA-483), were presented to and discussed with you at the conclusion of the inspection. These items of concern include, but are not limited to, the following:\n\n1) Failure to process HCT\u002FPs in a way that does not cause contamination or cross-contamination during processing and that prevents the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FP [21 CFR 1271.220(a)]. Specifically:\n\na. Your establishment processes multiple batches of Freeze-Dried Particulate Bone from a single donor on the same day, by the same processing technician, under the same environmental conditions, and using the same equipment. Cleaning of equipment and facilities is not performed in (b)(4) each batch. Post-processing cultures of vials from one or more batches from a single donor tested positive for microorganisms, several of which were identified on multiple occasions. Although positive microbiological cultures were found in some batches, other batches from the same donor were distributed. For example:\n\ni. On November 16, 2021, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). A post-processing culture was positive for Bacillus (not anthracis) in one batch manufactured from this donor.\n\nii. On July 7, 2021, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). Post-processing cultures were positive for Stenotrophomonas maltophilia in two batches manufactured from this donor.\n\niii. On May 13, 2021, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). Post-processing cultures were positive for Stenotrophomonas maltophilia or Pseudomonas aeruginosa in four batches manufactured from this donor.\n\niv. On April 30, 2020, (b)(4) batches of Freeze-Dried Particulate Bone were manufactured from donor (b)(6). A post-processing culture was positive for Micrococcus luteus in one batch manufactured from this donor.\n\nb. During the inspection, the FDA investigator observed processing of HCT\u002FPs, from donor (b)(6) on December 28, 2021, that significantly increased the potential for contamination and did not prevent the introduction, transmission, or spread of communicable disease through the use of the HCT\u002FPs. Specifically, the investigator noted the high velocity return air slots of the (b)(4) Laminar Flow Bench, located along the front edge of the work surface and that provide protection from a “backwash” of dirty air into the work area, were covered with a sterile sheet\u002Fdrape.\n\n2) Failure to validate and approve processes according to established procedures where the results of processing cannot be fully verified by subsequent inspections and tests [21 CFR 1271.230(a)]. For example:\n\nYou failed to adequately validate the manufacturing process for the Flexo-Plate, and Flexo-Membrane, and Freeze-Dried Particulate Bone products. Your “Processing of Flexo-plate and Membrane Grafts Process Qualification Summary Report” (dated October 14, 2019) and “Processing of Particulate Tissue Process Qualification Summary Report” (dated October 4, 2019) fail to include in-process microbiological testing to ensure that you are not introducing contamination during processing and that your process removes any contamination present. In addition, the documents noted above do not include any acceptance criteria related to microbiological contamination of HCT\u002FPs or the types of microorganisms typically encountered on such HCT\u002FPs.\n\n3) Failure to monitor environmental conditions where they could reasonably be expected to cause contamination or cross contamination of HCT\u002FPs or equipment, or accidental exposure of HCT\u002FPs to communicable disease agents [21 CFR 1271.195(c)]. For example:\n\nYour January 2020 through November 2021 processing session logs indicate that you conduct environmental monitoring for microorganisms approximately (b)(4). Additionally, you do not perform environmental monitoring during processing. The introduction, transmission, or spread of communicable diseases could reasonably be expected to occur during processing, therefore, you would be expected to perform environmental monitoring for microorganisms during processing.\n\n4) Failure to investigate HCT\u002FP deviations and trends of HCT\u002FP deviations relating to core CGTP requirements. Under the applicable regulation, each investigation must include a review and evaluation of the HCT\u002FP deviation, the efforts made to determine the cause, and the implementation of corrective action(s) to address the HCT\u002FP deviation and prevent recurrence [21 CFR 1271.160(b)(6)]. Specifically:\n\na. After the issuance of an Untitled Letter dated July 22, 2019, you submitted an initial HCT\u002FP deviation report to FDA on September 17, 2019, regarding the distribution of HCT\u002FPs after receipt of positive post-processing cultures. You submitted supplemental information on November 1, 2019, and April 14, 2020. The deviation reports stated you performed an investigation and proposed the reason for the positive post-processing cultures as inadvertent contamination of the sample at the microbiology laboratory when the plastic pouch containing the sample was opened by the testing laboratory that performed the microbiological testing.\n\nAs noted above, you continued to have positive post-processing cultures. You subsequently opened 22 investigations of positive post-processing cultures for bone products processed between April 2020 and December 2021; however, the investigations were closed and once again, you failed to identify corrective actions to address the ongoing deviations and to prevent their recurrence. For example:\n\ni. On May 24, 2021, post-processing cultures for Freeze-Dried Particulate Bone from donor (b)(6) tested positive for Stenotrophomonas maltophilia and Pseudomonas aeruginosa. You opened “HCT\u002FP Deviation #005” after the initiation of the inspection and closed the investigation on December 7, 2021.\n\nii. On May 8, 2020, post-processing cultures for Freeze-Dried Particulate Bone from donor (b)(6) tested positive for Micrococcus luteus. You opened “HCT\u002FP Deviation #001” after the initiation of the inspection and closed the investigation on December 7, 2021.\n\nb. Between January 2020 and November 2021, you performed environmental monitoring prior to cleaning your processing room, which resulted in 10 positive microbiological cultures from the (b)(4), one positive microbiological culture from the (b)(4) used for multiple processing steps to include (b)(4), and one positive microbiological culture from the (b)(4) Laminar Flow Bench. For example:\n\ni. On July 29, 2021, an environmental settling plate (S-072221-09235) from the (b)(4) table tested positive for Fungi, and Bacillus species (not anthracis). You opened “HCT\u002FP Deviation #E002” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\n\nii. On July 12, 2021, an environmental settling plate (S-070421-03649) from the (b)(4) Laminar Flow Bench tested positive for gram-positive cocci and Staphylococcus petrasii. You opened “HCT\u002FP Deviation #E001” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\n\niii. On September 8, 2020, an environmental touch plate (S-090220-08144) from the (b)(4) tested positive for Bacillus species (not anthracis), coagulase-negative Staphylococcus, and Bacillus marisflavi. You opened “HCT\u002FP Deviation #E-006” after the initiation of the inspection; however, it was closed on December 7, 2021, without an investigation or implementation of corrective actions to prevent recurrence.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies. It is your responsibility to ensure that your establishment is operating in compliance with all the applicable regulatory requirements. You are responsible for reviewing your firm’s operations as a whole to ensure that you fully comply with the law.\n\nWe acknowledge receipt of your letter dated February 23, 2022, in response to the Form FDA-483, issued to your establishment at the close of the inspection. We have reviewed the corrective actions outlined in the response and we have the following comments:\n\n1. In your response to Observation 1, under paragraph 1(a), your revised SOP 110-006, Release of Processed Tissues states, “... in the event of a positive culture(s) the entire number of batches processed from the same donor during a processing session will be discarded.” Your response does not address your plan for the HCT\u002FPs you have already processed in violation of 21 CFR 1271 that have already been distributed, as well as the HCT\u002FPs that currently remain in storage.\n\n2. In response to Observation 2, under paragraph 2(b) you stated you would, “Revalidate entire process for Processing of Flexo-Plate & Flexo-Membrane Grafts and Particulate Tissue.” We note that under 21 CFR 1271.230(a), process validation must be performed before manufacturing HCT\u002FPs. Your response does not indicate that you will halt processing of Flexo-Plate & Flexo-Membrane Grafts and Particulate Tissue products until your processes have been validated.\n\n3. In response to Observations 4 and 5, you stated that “CAPA#002, Manufacturing monitoring to mitigate contamination” and “CAPA#003, Environmental monitoring” were initiated as corrective actions and that they would be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\n\n4. In response to Observation 6, you stated that CAPA #001, “Quality Program Continuous Improvement and Enforcement” was initiated that includes drafting a new SOP on how to perform investigations detailing root cause analysis to be completed by April 2022. Your changes will be reviewed during the next inspection of your establishment to confirm compliance with 21 CFR 1271.\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. If you believe that your product is not in violation of the law, include your reasoning and any supporting information for our consideration. Additionally, include any documentation necessary to show that correction of any of the above-noted violations has been achieved. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame within which the remaining corrections will be completed.\n\nGiven the seriousness of these violations, we also request your attendance at a Regulatory Meeting, within 30 calendar days of receipt of this letter, to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. We will host the meeting virtually on Zoom. This meeting will also allow you to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or by email at Colleen.Aspinwall@fda.hhs.gov for confirmation of the meeting date and time. A call-in phone number for the Zoom meeting will be provided at that time.\n\nYour response should be emailed to Colleen.Aspinwall@fda.hhs.gov. If you should have any questions, please contact Colleen Aspinwall, Compliance Officer, at (561) 416-1065, ext. 1105 or via email.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division I","OsteoLife Biomedical I LLC","osteolife-biomedical-i-llc-626889-03312022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fosteolife-biomedical-i-llc-626889-03312022","2026-10-26T08:09:39.546205+00:00","2022-05-31","626889","Biologics","Theodore I. Malinin, MD","2026-08-20T01:51:41.829+00:00","2022-03-31",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":111,"closeout_date":19,"issuing_office":100,"recipient_name":112,"body_fetched_at":113,"delivery_method":114,"recipient_title":19,"reference_number":19,"action_taken_date":115,"medical_device_id":19,"response_letter_date":19},3260,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2021-07-13T13:20:00Z\">07\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-01T04:00:00Z\">07\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021\">Biomedical Research Laboratories, LLC\u003C\u002Fa>","Office of Human and Animal Food Operations –West Division 5","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher Jacob\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomedical Research Laboratories, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7590 Fay Ave Suite 202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>La Jolla\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92037-4885\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations –West Division 5\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>July 1, 2021\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL 612831\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jacob:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Calm Legs\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Calm Legs product page:\u003Cbr>\n&nbsp; o “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\u003Cbr>\n&nbsp; o “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\u003Cbr>\n&nbsp; o “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\u003Cbr>\n&nbsp; o “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\u003Cbr>\n&nbsp; o “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\u003Cbr>\n&nbsp; o “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\u003Cbr>\n&nbsp; o “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\u003Cbr>\n&nbsp; o “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\u003Cbr>\n• On the blog post “Hope for RLS Sufferers”:\u003Cbr>\n&nbsp; o “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\u003Cbr>\n&nbsp; o “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\u003Cbr>\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\u003Cbr>\n&nbsp; o “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\u003Cbr>\n• On the blog post “How Stress Impacts RLS”:\u003Cbr>\n&nbsp; o “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\u003Cbr>\n• On the blog post “What is Restless Legs Syndrome?”:\u003Cbr>\n&nbsp; o “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\u003Cbr>\nOn your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\u003Cbr>\n• An embedded YouTube video includes the following claims:\u003Cbr>\n&nbsp; o “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\u003Cbr>\n&nbsp; o “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\u003C\u002Fp>\n\n\u003Cp>On the Native Origins Facebook page:\u003Cbr>\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\u003Cbr>\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\u003Cbr>\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\u003Cbr>\n• “Natural Remedy for RLS”\u003Cbr>\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\u003Cbr>\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Flexify\u003C\u002Fstrong>\u003Cbr>\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\u003Cbr>\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\u003Cbr>\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\u003Cbr>\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\u003Cbr>\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\u003Cbr>\n&nbsp; o “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\u003Cbr>\n&nbsp; o “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\u003Cbr>\n&nbsp; o “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\u003Cbr>\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\u003Cbr>\n&nbsp; o “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Collagen Peptides\u003C\u002Fstrong>\u003Cbr>\nOn your product website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Collagen Peptides product page:\u003Cbr>\n&nbsp; o “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\u003Cbr>\n• On the blog post “What Are the Health Benefits of Collagen?”:\u003Cbr>\n&nbsp; o “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\u003Cbr>\n&nbsp; o “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\u003Cbr>\n• On the blog post “4 Ways to Add Collagen to Your Day”:\u003Cbr>\n&nbsp; o “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\u003Cbr>\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\u003Cbr>\n&nbsp; o “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\u003Cbr>\n• On the blog post “Collagen and Joint Health”:\u003Cbr>\n&nbsp; o “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\u003Cbr>\n&nbsp; o “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohemia\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Prohemia product page:\u003Cbr>\n&nbsp; o “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\u003Cbr>\n&nbsp; o “Prohemia contains several potent antioxidants to reduce inflammation . . .”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\u003Cbr>\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Altitude RX\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Altitude RX product page:\u003Cbr>\n&nbsp; o “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\u003Cbr>\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\u003Cbr>\n&nbsp; o “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\u003Cbr>\n&nbsp; o “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\u003Cbr>\n&nbsp; o “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\u003Cbr>\n&nbsp; o “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlsports.com:\u003Cbr>\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\u003Cbr>\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\u003Cbr>\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fbrlscience.com:\u003Cbr>\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\u003Cbr>\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\u003Cbr>\n\u003Cbr>\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\u003C\u002Fp>\n\n\u003Cp>The above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\u003Cbr>\n• “Take Altitude RX for altitude sickness prevention…”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Trimmunity\u003C\u002Fstrong>\u003Cbr>\nOn your website https:\u002F\u002Fnativeorigins.com:\u003Cbr>\n• On the Trimmunity product page:\u003Cbr>\n&nbsp; o “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\u003Cbr>\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\u003Cbr>\n&nbsp; o “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\u003Cbr>\n&nbsp; o “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\u003Cbr>\n&nbsp; o “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\u003Cbr>\n&nbsp; o “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\u003Cbr>\n&nbsp; o “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\u003C\u002Fp>\n\n\u003Cp>Your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number 612831 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations –West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher Jacob\n\nRecipient Title\n\nCEO\n\nBiomedical Research Laboratories, LLC\n\n7590 Fay Ave Suite 202\n\nLa Jolla, CA 92037-4885\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations –West Division 5\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2021\n\nWL 612831\n\nDear Mr. Jacob:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fnativeorigins.com and https:\u002F\u002Fbrlsports.com in May 2021 and has determined that you take orders at https:\u002F\u002Fnativeorigins.com for your Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products, and that you take orders at https:\u002F\u002Fbrlsports.com for your Flexify and Altitude RX products. We have also reviewed your website https:\u002F\u002Fbrlscience.com and your social media website at http:\u002F\u002Fwww.facebook.com\u002Fmynativeorigins, which direct consumers to your website https:\u002F\u002Fnativeorigins.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nCalm Legs\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Calm Legs product page:\n\no “Are you suffering with symptoms of Restless Legs Syndrome? . . . Calm Legs provides natural relief from the jumpy legs and fatigue associated with RLS.”\n\no “For many users, Calm Legs brings rapid relief from Restless Legs Syndrome...”\n\no “Calm Legs is the first natural supplement to address nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce its symptoms. Calm Legs is the only RLS natural supplement that contains the seven natural ingredients clinically proven to relieve RLS symptoms. To learn more, read our blog post, ‘How Do the Ingredients in Calm Legs Relax Restless Legs?’”\n\no “Each ingredient in the Calm Legs formula has been clinically tested and shown to reduce symptoms of RLS.”\n\n• On the blog post “How Do the Ingredients in Calm Legs Relax Restless Legs?”:\n\no “Calm Legs was the first natural supplement to address recently discovered nutrient deficiencies associated with Restless Legs Syndrome (RLS) while helping to reduce symptoms of RLS.”\n\no “Researchers have suggested that valerian [an ingredient in Calm Legs] is a safe herb for managing RLS without side effects.”\n\no “Restless legs are linked to bad circulation and unhealthy blood vessels. Vitamin C [an ingredient in Calm Legs] is famous for promoting flexible, healthy blood vessels. Vitamin C also boosts iron absorption, ‘regenerates’ Vitamin E and enhances circulation to the legs and feet. Research has found that vitamin C supplementation brings significant reductions in Restless Legs (RLS) symptoms.”\n\no “Vitamin E [an ingredient in Calm Legs] is an RLS symptom relief multitasker that promotes flexible arteries, boosts leg circulation, modulates inflammation and supports healthy nervous system function. Research has shown that vitamin E supplementation was associated with ‘prompt and gratifying relief’ of nighttime leg cramping.”\n\n• On the blog post “Hope for RLS Sufferers”:\n\no “Here’s the real breakthrough: A specific combination of these natural compounds taken in precise ratios appears to unlock lasting RLS relief. This combination is found in Calm Legs.”\n\no “Calm Legs combines seven different, clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market. Calm Legs is producing results that many RLS sufferers, including Susan Thompson, call life- changing. After taking Calm Legs for three months, Susan stated: ‘Calm Legs gave me my life back. I'm sleeping better than I have in years. I feel happy and energetic. My legs are no longer jumpy. And no weird side effects! I feel like myself again.’”\n\n• On the blog post “Top 5 Natural Therapies for Restless Legs”:\n\no “Calm Legs restores these depleted nutrients, addressing multiple aspects of RLS to provide soothing relief.”\n\n• On the blog post “How Stress Impacts RLS”:\n\no “Calm Legs also contains four other vitamins (vitamin C, vitamin E, folic acid, and vitamin B12) that have been clinically shown to . . . manage inflammation . . . and overall reduce symptoms of RLS . . . ”\n\n• On the blog post “What is Restless Legs Syndrome?”:\n\no “RLS can lead to a number of consequences, none of them good, including depression, sadness, sleep deprivation, memory loss, stress and fatigue. Since its causes are likely multiple and largely unknown, and there is no known cure, the current approach is to treat the symptoms. Calm Legs is a safe, natural remedy that has helped thousands of people relax and get a good night’s sleep. Order Calm Legs today for rapid relief from RLS...”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Calm Legs combines seven different clinically studied RLS relief nutrients into one tablet to make the most comprehensive remedy on the market.”\n\n• An embedded YouTube video includes the following claims:\n\no “CALM LEGS IS THE SOLUTION FOR RESTLESS LEGS!”\n\no “The key a new supplement called Calm Legs that’s been featured on WebMD and in Prevention Magazine. Calm Legs helps RLS sufferers wake up refreshed and alert, experience deep restful sleep, and provides lasting relief from restless legs.”\n\nOn the Native Origins Facebook page:\n\n• “You don’t have to endure the unpleasant side effect that sometimes accompany RLS drugs. #RLS #restlesslegs #nativeorigins #calmlegs” [from an August 6, 2019 post]\n\n• “Stress is a major trigger for RLS. Find out how you can manage both ailments with natural remedies. #rls @nativeorigins #calmlegs #stress #rlstriggers” [from a July 29, 2019 post]\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Feel more relaxed throughout the day and get restless leg relief with Calm Legs. Soothe jumpy leg muscles with natural supplements for restless legs syndrome.”\n\n• “Try our supplements for restless leg syndrome and relive [sic] sensations of itching, tingling, crawling, and the urge to move legs. Learn about Calm Legs today!”\n\n• “Natural Remedy for RLS”\n\n• “Discover how the ingredients and vitamins in Calm Legs help reduce the symptoms of restless leg syndrome where other prescription drug therapies fall short.”\n\n• “Learn more about Calm Legs, a natural remedy for RLS that offers relief from jumpy-jerky legs, creepy crawly sensations, and random kicking.”\n\nFlexify\n\nOn your websites https:\u002F\u002Fbrlsports.com and https:\u002F\u002Fnativeorigins.com:\n\n• \"What are early signs of arthritis? . . . Used consistently, Flexify will help alleviate painful joint stiffness, joint discomfort... If you are experiencing pain in your elbows, knees, hips, thumbs, shoulders or fingers, you can expect relief from aches and soreness...\"\n\n• “Boswellia [an ingredient in Flexify] has been clinically shown to significantly decrease joint pain and improve joint function within seven days of use.”\n\n• “Glucosamine, chondroitin, and MSM [ingredients in Flexify] are well-studied ingredients for...relief from arthritis.”\n\n• “Ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen when taken daily for hip and knee arthritis pain.”\n\n• “Turmeric [an ingredient in Flexify] reduces joint pain and swelling by blocking inflammatory cytokines and enzymes.”\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the blog post “How Do the Ingredients in Flexify Help Relieve Pain and Nourish Joints?”:\n\no “[G]lucosamine [an ingredient in Flexify] supplementation significantly reduced the symptoms of osteoarthritis in the lower limbs and delayed the structural progression of osteoarthritis.”\n\no “Boswellia [an ingredient in Flexify] extracts can be an effective painkiller and have anti-inflammatory properties that may prevent the loss of cartilage. Research shows that boswellic acid can prevent the formation of leukotrienes in the body. Leukotrienes are molecules that have been identified as a cause of inflammation which may inhibit the autoimmune process.”\n\no “Taken daily, ginger [an ingredient in Flexify] has been shown to work about as well as ibuprofen for hip and knee arthritis pain. Ginger has been shown to have anti-inflammatory properties similar to ibuprofen and COX-2 inhibitors (e.g., Celebrex). In a 2012 study, a specialized ginger extract was as effective in reducing inflammatory reactions in RA as steroids. Earlier studies showed that taking a certain extract four times daily reduced osteoarthritis pain in the knee after three months of treatment, and another taken twice daily worked about as well as ibuprofen taken three times daily for hip and knee OA pain.”\n\n• On the blog post “5 Ways to Prevent Osteoarthritis in Athletes”:\n\no “Flexify Advanced Joint Support is used by athletes and others affected by arthritis... Each tablet contains seven clinically tested, natural ingredients that help build and maintain healthy joints and cartilage, slowing the progression of osteoarthritis or preventing it completely.”\n\nCollagen Peptides\n\nOn your product website https:\u002F\u002Fnativeorigins.com:\n\n• On the Collagen Peptides product page:\n\no “Some studies have suggested that collagen supplementation may help lower your risk for heart disease . . . by reducing arterial stiffness and boosting ‘good’ HDL cholesterol.”\n\n• On the blog post “What Are the Health Benefits of Collagen?”:\n\no “Research suggests that collagen peptide supplementation may also be effective in reducing pain and inflammation associated with chronic conditions like osteoarthritis.”\n\no “If you’re looking to relieve aches and pains from joint stiffness…Native Origins Collagen Peptides may be a good option to add to your daily routine.”\n\n• On the blog post “4 Ways to Add Collagen to Your Day”:\n\no “A 2018 systematic review published in the British Journal of Sports Medicine, researchers found that collagen supplements provided short-term relief from osteoarthritis-associated pain.”\n\n• On the blog post “How Do Collagen Peptides Support Healthy Hair, Skin, Nails and Joints?”:\n\no “The major type of collagen found in cartilage, collagen type II is frequently used in applications intended to help relieve pain from conditions like rheumatoid arthritis. . . . A 2015 study found that adding type II collagen from chicken [an ingredient in Collagen Peptides] to the diet of people with rheumatoid arthritis was effective in reducing pain, stiffness and swelling of joints.”\n\n• On the blog post “Collagen and Joint Health”:\n\no “Some studies have shown that taking collagen supplements may help increase bone mineral density, protect joint cartilage, and even reduce joint pain associated with arthritis.”\n\no “Collagen . . . may help reduce pain, stiffness and swelling of the joints”\n\nProhemia\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Prohemia product page:\n\no “Prohemia helps support healthy blood levels in individuals suffering from symptoms associated with anemia.”\n\n• On the blog post “How Do the Ingredients in Prohemia Fight Anemia-Related Fatigue and Improve Stamina?”:\n\no “Prohemia contains several potent antioxidants to reduce inflammation . . .”\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Prohemia, promotes red blood cell production, . . . promotes hemoglobin production, and improves energy level and stamina in individuals with anemia.”\n\n• The featured testimonial: “Mom had a stroke on Procrit. Since starting Prohemia she has not needed any more transfusions. Her hemoglobin went from 9.3 G\u002FdL to 11.8 g\u002FdL.”\n\nAltitude RX\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Altitude RX product page:\n\no “The active components in Altitude RX have been demonstrated to increase oxygen levels and reduce symptoms of Acute Mountain Sickness.”\n\no “Reduce the debilitating symptoms caused by high altitude and vertigo with Altitude RX”\n\n• On the blog post “How Do the Ingredients in Altitude RX Help Prevent Altitude Sickness?”:\n\no “Our scientists used the most potent compounds available in amounts shown to prevent symptoms of Acute Mountain Sickness.”\n\no “Science has demonstrated that Ginkgo biloba [an ingredient in Altitude RX] has a remarkable ability to increase blood flow throughout the body, enabling it to cope better with decreased atmospheric oxygen levels. Antioxidant properties in the leaf extract increase vasodilation and peripheral blood flow in the capillary vessels, as well as decreasing blood viscosity and helping to regulate cerebral energy metabolism.”\n\no “Rhodiola [an ingredient in Altitude RX] also has been shown to reverse the effects of asthenia. It reduces fatigue, labored breathing, rapid heart rate, sluggishness . . .”\n\no “ALA, Vitamin C and Vitamin E [ingredients in Altitude RX] work synergistically to protect cells from free radical damage.”\n\nOn your website https:\u002F\u002Fbrlsports.com:\n\n• “Altitude RX is a patent-pending formula of natural ingredients that takes a preventive approach to reducing AMS symptoms, including nausea, headache, fatigue, shortness of breath and insomnia.”\n\n• “Altitude RX is designed to safely and significantly increase oxygen levels at high altitude…”\n\n• “Ginkgo [an ingredient in Altitude RX] can help protect against altitude sickness through its ability to improve blood flow, and thus oxygen delivery to the brain.\"\n\nOn your website https:\u002F\u002Fbrlscience.com:\n\n• “Altitude RX patent-pending formula of all-natural ingredients takes a preventive approach to reducing Acute Mountain Sickness (AMS) symptoms.”\n\n• “One of the active ingredients in Altitude RX promotes increased blood flow throughout the body and decreases blood viscosity — which offsets the negative effects of the low oxygen levels found at high altitude. Better blood flow at altitude delivers more oxygen to your brain, eliminating headaches — and delivering more oxygen to your muscles...”\n\nFrom a July 22, 2019 post on the Native Origins Facebook page: “Don’t let altitude sickness slow you down. #altituderx #altitudesickness”\n\nThe above noted website claims are supplemented by metatags used to bring consumers to your website https:\u002F\u002Fnativeorigins.com through Internet searches. The metatags are:\n\n• “Take Altitude RX for altitude sickness prevention…”\n\nTrimmunity\n\nOn your website https:\u002F\u002Fnativeorigins.com:\n\n• On the Trimmunity product page:\n\no “Contains antioxidants to help fight off free radicals, which can damage cells and impact immune health.”\n\n• On the blog post “How Do the Ingredients in Trimmunity Help Improve Our Immune Defenses?”:\n\no “[E]lderberry [an ingredient in Trimmunity] is most often used to alleviate seasonal illness and respiratory challenges.”\n\no “Both human and animal studies have suggested that echinacea [an ingredient in Trimmunity] stimulates immune function and activates natural killer cells.”\n\no “Vitamin D [an ingredient in Trimmunity] helps minimize inflammation. . .”\n\no “Vitamin C [an ingredient in Trimmunity] supports the production and integrity of white blood cells, which help protect against infection.”\n\no “Zinc [an ingredient in Trimmunity] . . . works by . . . reducing inflammation... zinc may help prevent dangerous, out-of-control inflammation that can result from haywire immune responses.”\n\nYour Calm Legs, Flexify, Collagen Peptides, Prohemia, Altitude RX, and Trimmunity products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Calm Legs, Collagen Peptides, and Flexify are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Calm Legs, Collagen Peptides, and Flexify fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nRefer to Unique Identification Number 612831 when replying.\n\nIf you have any questions regarding this letter, please contact Elodie X. Tong-Lin, Compliance Officer, at elodie.tong-lin@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations –West Division 5","Biomedical Research Laboratories, LLC","biomedical-research-laboratories-llc-612831-07012021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomedical-research-laboratories-llc-612831-07012021","2026-10-26T08:08:05.137198+00:00","2021-07-13","612831","Food & Beverages","Mr. Christopher Jacob","2026-08-20T02:58:27.948+00:00","United Parcel Service","2021-07-01",{"id":117,"raw":118,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":127,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":132,"closeout_date":19,"issuing_office":11,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},21674,[119,120,121,11,122,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flovelace-biomedical-research-institute-725136-10062026\">Lovelace Biomedical Research Institute\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert W. Rubin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lovelace Biomedical Research Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2425 Ridgecrest Drive SE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 27-HFD-45-10-01\u003C\u002Fp>\u003Cp>Dear Mr. Rubin:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies:\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations found in the raw data were not documented in the final study report:\u003C\u002Fp>\u003Cp>1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing.\u003C\u002Fp>\u003Cp>2. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Intravenous Dosing and Blood Collection:\u003C\u002Fp>\u003Cp>a. Animal 3002, during dosing on October 16, 2023, laid on the cage bottom for one hour and ten minutes after infusion of the test article.\u003C\u002Fp>\u003Cp>b. Animals 3004 and 3005, during dosing on October 16, 2023, pulled out their venous catheters during infusion of the test article.\u003C\u002Fp>\u003Cp>c. Animals 1003 and 1004, during dosing on November 1, 2023, pulled out their venous catheters during infusion of the control article.\u003C\u002Fp>\u003Cp>d. Animal 4005, during dosing on November 11, 2023, had infiltration of the test article into the surrounding tissue of the left saphenous vein.\u003C\u002Fp>\u003Cp>Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following concerns and observations noted in the raw data were not documented in the final study report:\u003C\u002Fp>\u003Cp>3. The final study report did not include all the abnormal cageside clinical observations for all 48 animals, documented between November 21, 2022, and July 13, 2023, including incidences of abnormal stool observations, such as bloody or dark-red, liquid, loose, mucoid, or unformed stools.\u003C\u002Fp>\u003Cp>4. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Inhalation Exposure and PK Blood Collection:\u003C\u002Fp>\u003Cp>a. Animal 2006, during dosing on January 10, 2023, had irregular breathing from the aerosol dosing system during the last few minutes of dosing.\u003C\u002Fp>\u003Cp>b. Animal 5008, during dosing on April 2, 2023, had irregular breathing and was removed from the aerosol dosing system intermittently.\u003C\u002Fp>\u003Cp>c. Animal 2004, during dosing on April 5, 2023, had irregular breathing and was removed from the aerosol dosing system after the first 30 minutes of the dose exposure.\u003C\u002Fp>\u003Cp>d. Animal 3004, on June 14, 2023, was not dosed due to a swollen muzzle.\u003C\u002Fp>\u003Cp>We acknowledge that this finding as described above was not included on the Form FDA 483 you received, and therefore your written response did not directly address the violation as discussed in this letter.\u003C\u002Fp>\u003Cp>In your May 9, 2025, written response to the Form FDA 483, regarding the abnormal cageside clinical observations, you stated that documentation of the review of Animal Management System records would be added to the study file, and an addendum would be added to the final study reports for Protocols \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by May 31, 2025. You also stated that SOP-1106 (Preparation of a Final Report) and SOP-1882 (Animal Records and Animal Study Data Maintained at LBRI) would be updated by June 15, 2025. Regarding the individual dosing-related issues, your written response acknowledged that the final reports did not specifically discuss individual dosing issues. You stated that documentation of the review of those issues would be added to the study file and an addendum would be added to the final reports, as appropriate, by May 31, 2025. We acknowledge receipt of the revised final study reports, both of which were dated May 30, 2025.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. Specifically, you did not provide sufficient details regarding the updated SOPs, including the nature of the proposed or completed updates. Your corrective action plan also did not include any training on the updated SOPs or on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. In addition, the revised final study reports did not completely address the individual dosing issues. Finally, your corrective action plan did not include a description of any planned audits to check for compliance with updated procedures, as applicable. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because the testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflected the raw data of the nonclinical laboratory studies, FDA is concerned about the integrity of the data generated and reported from nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, as well as any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>10\u002F06\u002F2026 10:05:58 AM\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert W. Rubin\n\nRecipient Title\n\nCEO\n\nLovelace Biomedical Research Institute\n\n2425 Ridgecrest Drive SE\n\nAlbuquerque, NM 87108\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 27-HFD-45-10-01\nDear Mr. Rubin:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Lovelace Biomedical Research Institute (LBRI) between April 7 and 18, 2025. The investigator representing FDA reviewed the role of LBRI as the testing facility for the following nonclinical laboratory studies:\nProtocol (b)(4): “(b)(4),” of the investigational drug (b)(4), performed for (b)(4)\nProtocol (b)(4): “(b)(4),” of the investigational drug (b)(4), performed for (b)(4)\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your May 9, 2025, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated May 9, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\nFailure of the quality assurance unit (QAU) to review the final study report to [en]sure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements.\nSpecifically, for Protocol (b)(4), the following observations found in the raw data were not documented in the final study report:\n1. For 20 out of 34 animals, the final study report did not include all the abnormal cageside clinical observations that were documented between October 1 and January 3, 2024, including but not limited to sneezing; runny or bloody nose; liquid, loose, mucoid, or semisolid stool; sunken eyes; swollen perineum; bloating; hunched posture; low appetite; and heavy breathing.\n2. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Intravenous Dosing and Blood Collection:\na. Animal 3002, during dosing on October 16, 2023, laid on the cage bottom for one hour and ten minutes after infusion of the test article.\nb. Animals 3004 and 3005, during dosing on October 16, 2023, pulled out their venous catheters during infusion of the test article.\nc. Animals 1003 and 1004, during dosing on November 1, 2023, pulled out their venous catheters during infusion of the control article.\nd. Animal 4005, during dosing on November 11, 2023, had infiltration of the test article into the surrounding tissue of the left saphenous vein.\nSpecifically, for Protocol (b)(4), the following concerns and observations noted in the raw data were not documented in the final study report:\n3. The final study report did not include all the abnormal cageside clinical observations for all 48 animals, documented between November 21, 2022, and July 13, 2023, including incidences of abnormal stool observations, such as bloody or dark-red, liquid, loose, mucoid, or unformed stools.\n4. The final study report did not include descriptions of the following dosing issues, which were recorded on the raw data forms for Inhalation Exposure and PK Blood Collection:\na. Animal 2006, during dosing on January 10, 2023, had irregular breathing from the aerosol dosing system during the last few minutes of dosing.\nb. Animal 5008, during dosing on April 2, 2023, had irregular breathing and was removed from the aerosol dosing system intermittently.\nc. Animal 2004, during dosing on April 5, 2023, had irregular breathing and was removed from the aerosol dosing system after the first 30 minutes of the dose exposure.\nd. Animal 3004, on June 14, 2023, was not dosed due to a swollen muzzle.\nWe acknowledge that this finding as described above was not included on the Form FDA 483 you received, and therefore your written response did not directly address the violation as discussed in this letter.\nIn your May 9, 2025, written response to the Form FDA 483, regarding the abnormal cageside clinical observations, you stated that documentation of the review of Animal Management System records would be added to the study file, and an addendum would be added to the final study reports for Protocols (b)(4) and (b)(4) by May 31, 2025. You also stated that SOP-1106 (Preparation of a Final Report) and SOP-1882 (Animal Records and Animal Study Data Maintained at LBRI) would be updated by June 15, 2025. Regarding the individual dosing-related issues, your written response acknowledged that the final reports did not specifically discuss individual dosing issues. You stated that documentation of the review of those issues would be added to the study file and an addendum would be added to the final reports, as appropriate, by May 31, 2025. We acknowledge receipt of the revised final study reports, both of which were dated May 30, 2025.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken and plans to take, your response is inadequate because you did not include sufficient details about your corrective action plan. Specifically, you did not provide sufficient details regarding the updated SOPs, including the nature of the proposed or completed updates. Your corrective action plan also did not include any training on the updated SOPs or on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. In addition, the revised final study reports did not completely address the individual dosing issues. Finally, your corrective action plan did not include a description of any planned audits to check for compliance with updated procedures, as applicable. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause the testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflected the raw data of the nonclinical laboratory studies, FDA is concerned about the integrity of the data generated and reported from nonclinical studies conducted at your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, as well as any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n10\u002F06\u002F2026 10:05:58 AM","Lovelace Biomedical Research Institute","lovelace-biomedical-research-institute-725136-10062026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flovelace-biomedical-research-institute-725136-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-13","725136","Drugs","Robert W. Rubin","2026-10-14T12:32:02.221+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2026-10-06",{"id":138,"raw":139,"subject":144,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":149,"fei_number":19,"letter_url":150,"updated_at":151,"action_type":22,"case_status":23,"posted_date":152,"marcs_cms_no":153,"product_type":111,"closeout_date":19,"issuing_office":143,"recipient_name":154,"body_fetched_at":155,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":156,"medical_device_id":19,"response_letter_date":19},1441,[140,141,142,143,144,13,13,13],"\u003Ctime datetime=\"2024-05-28T13:20:00Z\">05\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-09T04:00:00Z\">05\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024\">Biomic Sciences, LLC dba ION Intelligence of Nature\u003C\u002Fa>","Division of Human and Animal Food Operations East II","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Zachary Bush\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biomic Sciences, LLC dba ION Intelligence of Nature\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4351 Seminole Trail\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Charlottesville\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22153-2823\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 9, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS #667601\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Bush,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4351 Seminole Trail, Charlottesville, Virginia from June 12 through August 31, 2023. Based on inspectional findings and review of the product labels collected during the inspection, as well as review of your website at www.Intelligenceofnature.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on August 31, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. We address your responses below, when relevant information from such response(s) pertained to a particular issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>FDA Tested Samples\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>FDA conducted laboratory testing of a lot of ION Intelligence of Nature Sinus Support Nasal Spray drug product and results demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis determined that a sample of your ION Intelligence of Nature Sinus Support Nasal Spray drug product was grossly contaminated with microorganisms. This gross contamination is particularly concerning because your drug product is a nasal spray.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory testing of ION Intelligence of Nature Sinus Support Nasal Spray drug product lot 2302081HGA found gross microbial contamination. The individual sample results varied between 510,000 and up to 1,100,000 colony forming units (CFU)\u002FmL for total aerobic microbial count and between 290 and up to 1,100 CFU\u002FmL for total yeast and mold counts. Therefore, this drug product is adulterated under section 501(a)(1) of the Act.\u003C\u002Fp>\n\n\u003Cp>Microorganisms identified included \u003Cem>Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii)\u003C\u002Fem>, and \u003Cem>Paenibacillus sp.\u003C\u002Fem> The high bioburden in conjunction with the route of administration with this drug product poses a high risk of harm to vulnerable patients.\u003C\u002Fp>\n\n\u003Cp>On September 22, 2023, the FDA held a teleconference with you. During the teleconference, you agreed to conduct a voluntary recall of all lots of ION Intelligence of Nature Sinus Support Nasal Spray.\u003C\u002Fp>\n\n\u003Cp>On September 29, 2023, you voluntarily recalled all lots of ION Intelligence of Nature Sinus Support Nasal Spray, ION Sinus, and Restore Sinus Spray products to the consumer level due to microbial contamination identified as \u003Cem>Microbacterium sp., Fictibacillus sp., Bacillus sp.\u003C\u002Fem> (primarily \u003Cem>B. malikii\u003C\u002Fem>), and \u003Cem>Paenibacillus sp\u003C\u002Fem>., as noted on the following FDA website:\u003Cbr>\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbiomic-sciences-issues-voluntary-nationwide-recall-ion-sinus-support-ion-sinus-and-restore-sinus\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from June 12 through August 31, 2023, identified significant violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\u003C\u002Fp>\n\n\u003Cp>Your firm released finished drug product without adequate testing for critical microbial attributes (i.e., testing to ensure absence of objectionable microorganisms). Without appropriate testing of each lot of drug product required to be free of objectionable microorganisms prior to release, you did not have scientific evidence that the lots were free of microbial contamination that is objectionable in view of its intended use. Particularly for a drug product that is intended for use as a nasal spray, it is essential that your drug products are tested for microbial contamination to minimize the risk of patient exposure to significant numbers or harmful species of microorganisms, harmful microbial metabolites and\u002For toxins, and drug spoilage or degradation.\u003C\u002Fp>\n\n\u003Cp>You also stated during the inspection that you add \u003Cstrong>(b)(4)\u003C\u002Fstrong> to numerous drug product formulations to control microbial growth. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug product and cannot be relied on to reduce in-process bioburden during manufacturing. Additionally, long term use of medicinal compounds containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> may \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure that have led to \u003Cstrong>(b)(4)\u003C\u002Fstrong> documented and therefore, it is not possible to establish minimum levels that are safe.\u003C\u002Fp>\n\n\u003Cp>In your September 22, 2023, response, you state that you stopped producing and discontinued sales of the current formulation of ION Intelligence of Nature Sinus Support but plan to market a nasal product in the future. You state that you are revising your written procedures for quality unit (QU) responsibilities, including to specifically establish adequate testing of your finished product and water used in production of your products. You also state that you are revising procedures to ensure all applicable tests impacting the identity, strength, quality, and purity of your products are established and performed.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you plan to resume manufacturing drug products at this facility in the future for marketing in the United States. We request that you notify this office before you market such drug products.\u003C\u002Fp>\n\n\u003Cp>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate QU with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Adequate procedures that are designed to prevent objectionable microbiological contamination of drug products (21 CFR 211.113(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate testing of components with potential for microbiological contamination that is objectionable in view of its intended use (21 CFR 211.84(d)(6)).\u003C\u002Fli>\n\t\u003Cli>Procedures are followed to adequately establish, review, and approve master manufacturing records prior to use (21 CFR 211.100(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate batch records to document the mixing and packaging of your drug product (21 CFR 211.188).\u003C\u002Fli>\n\t\u003Cli>Establishment of an adequate stability program to support expiration dating of your drug products (including microbiological attributes) (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Adequate documentation for QU review and release of drug product. (21 CFR 211.22(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your QU was unaware of the identity of numerous proprietary components used to manufacture many of your drug products, and therefore could not have fulfilled their QU responsibilities to ensure all components meet established specifications for identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. You may refer to FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>Adulterated &amp; Misbranded Dietary Supplements\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Adulterated Low Acid Canned Food Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility on June 12 through August 31, 2023, identified serious violations of the Emergency Permit Control regulation Title 21, Code of Federal Regulations (CFR), Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). These violations cause your products to be adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of low acid canned food products, you are required to comply with the Act and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113.\u003C\u002Fp>\n\n\u003Cp>1. You did not register with the FDA as a commercial processor of low-acid foods. A commercial processor of low-acid foods is required, not later than 10 days after first engaging in the manufacture, processing, and packaging of thermally processed low-acid foods in hermetically sealed containers in any state, as defined in section 201(a)(1) of the Act, to register and file a Form FDA 2541 (food canning establishment registration) with the FDA, as required by 21 CFR 108.35(c)(1). However, your firm processes Ion Gut Support, a low-acid food, without registering with the FDA.\u003C\u002Fp>\n\n\u003Cp>2. You must file the scheduled processes with the FDA for each low-acid food in each container size as required by 21 CFR 108.35(c)(2). This filing must occur not later than 60 days after registration and prior to the packing of a new product and include the processing method, type of retort or other thermal processing equipment employed, minimum initial temperatures, times and temperatures of processing, sterilizing value, or other equivalent scientific evidence of process adequacy, critical control factors affecting heat penetration, and source and date of the establishment of the process, for each product in each container size. Specifically, as noted during the inspection, your firm did not file a scheduled process with FDA for your Ion Gut Support product. Further, a scheduled process shall be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of, as required by 21 CFR 113.83\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have initiated contact with a process authority, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We acknowledge that you have initiated actions. However, this violation remains uncorrected.\u003C\u002Fp>\n\n\u003Cp>Scheduled process information for low-acid foods processed by retort must be submitted on Form FDA 2541d (Food Process Filing for Low-Acid Retorted Method) and low-acid foods controlled by water activity must be submitted on Form FDA 2541f (Food Process Filing for Water Activity\u002FFormulation Control Method). More information on registration and filing can be found in the publication “Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format” available at http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Violations of Dietary Supplement CGMPs\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from June 12 through August 31, 2023, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Ion Gut Support dietary supplement to be adulterated within the meaning of section 402(g)(1) of the Act, 21 U.S.C. 342(g)(1), because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of dietary supplement CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish identity specifications for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1); component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2); and limits on those types of contamination that may adulterate, or that may lead to adulteration, of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3).\u003C\u002Fp>\n\n\u003Cp>For your components, you purport to use your Biomic Sciences Component Specification sheets as your specifications for raw components \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your Ion Gut Support. However, these specification sheets do not include identity specifications for any of these components, as required by 21 CFR 111.70(b)(1); do not establish component specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or components \u003Cstrong>(b)(4)\u003C\u002Fstrong> that will ensure the purity of your Ion Gut Support, as required by 21 CFR 111.70(b)(2); and do not establish contamination specifications for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 111.70(b)(3). \u003Cstrong>(b)(4)\u003C\u002Fstrong> is susceptible to having contaminants not limited to microorganisms and heavy metals.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated September 22, you state that you are establishing identity component specifications and acceptance criteria using appropriate scientifically valid methods. However, you do not present any supporting evidence for us to evaluate your correction. Your response dated October 31 provides specifications that are for microbial contamination only and does not demonstrate that the requirements of 21 CFR 111.70(b) are met. Your November 15, 2023, and April 24, 2024, responses do not address this citation.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish product specifications for the identity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). For example, your product label for ION Gut Support lists the content of Humic Extract (from Ancient Soil) in the product as 5 mg; however, you have not established a strength specification for a finished batch of product to ensure that the label claim is met. For each specification you are required to establish and must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75. You must also ensure any tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. Your October 31, 2023, response provided finished product specifications for ION Gut Support (SPC-01). However, the documents you provided do not demonstrate that you have corrected the above-mentioned deficiencies. Your remaining responses did not address this issue.\u003C\u002Fp>\n\n\u003Cp>3. You failed to quarantine components before you used them in the manufacture of a dietary supplement until quality control could conduct the required review and approval of such components, as required per 21 CFR 111.155(c). Specifically, during the inspection, our investigator observed that you did not place \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used in the manufacture of your Ion Gut Support, into quarantine for evaluation and release by Quality Control prior to use. Additionally, you have no records that document you quarantined, sampled, and analyzed select components prior to their use. As an example, you received \u003Cstrong>(b)(4)\u003C\u002Fstrong> from your supplier on January 17, 2022. You did not document the quarantine, sampling, or analysis of this component. You used this component on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You then used this \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the manufacturing of Ion Gut Support, 8-oz., Lot 2303301HBA, which was released into commerce.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your October 31, 2023, response, you state you have established a quarantine area in “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and provided a photograph. However, you did not present any records or evidence that components are being quarantined, sampled, and analyzed in accordance with your written procedure. Your remaining responses did not address this issue. Therefore, your responses fail to demonstrate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record failed to include all the information required under 21 CFR 111.260. Specifically, we reviewed your batch production record for Ion Gut Support and found it failed to contain the following required information:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained (21 CFR 111.260(c)).\u003C\u002Fli>\n\t\u003Cli>The identity and weight or measurement of water and \u003Cstrong>(b)(4)\u003C\u002Fstrong> components in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively (21 CFR 111.260(e)).\u003C\u002Fli>\n\t\u003Cli>Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the initials of the person responsible for verifying the weight or measure of each component used in the batch, the initials of the person responsible for adding the component to the batch, and the initials of the person responsible for verifying the addition of components to the batch (21 CFR 111.260(j)(2)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated October 31, 2023, you provided the MPR template for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, it does not include all elements as required in 21 CFR 111.260. Your remaining responses did not address this issue.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for calibrating instruments and controls you use in manufacturing or testing a component or dietary supplement, as required by 21 CFR 111.25(a). Specifically, you have not established written procedures for calibrating your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which you use in the manufacturing or testing of your Ion Gut Support.\u003C\u002Fp>\n\n\u003Cp>We have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. However, none of your responses provided documentation to demonstrate that you have established and followed written procedures for calibrating your&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, we cannot evaluate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Misbranding of Dietary Supplement Products\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the Ion Gut Support dietary supplement product you manufacture and distribute is misbranded under section 403 of the Act, 21 U.S.C. 343, because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Ion Gut Support dietary supplement products are misbranded within the meaning of Section 403(i)(2) of the Act, 21 U.S.C. 343(i)(2), in that the product labels fail to declare all the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4.\u003C\u002Fp>\n\n\u003Cp>The Supplement Facts panel of your product identifies “Humic Extract” as the active ingredient with only “Purified water” as the other ingredient. We reviewed and collected your batch production records, which document formulation, of all sizes of your Ion Gut Support product. According to your batch production records, your Ion Gut Support includes the following ingredients: \u003Cstrong>(b)(4) \u003C\u002Fstrong>purified water,\u003Cstrong> (b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Each ingredient must be declared by the common or usual name in descending order of predominance within the ingredient list unless an exemption is provided in 21 CFR 101.100, or a collective (generic) name is provided in 21 CFR 101.4.\u003C\u002Fp>\n\n\u003Cp>In your response, you state your components, other than humic extract,&nbsp;are processing aids to create the extraction. However, you provide no evidence these components are not present in the finished product. Further, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product (which is a product that consists of: \u003Cstrong>(b)(4)\u003C\u002Fstrong> are added after the extraction process. Thus, they are not processing aids as defined under 21 CFR 101.100(a)(3)(ii). Therefore, your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>2. Your Ion Gut Support products are misbranded under 403(q)(5)(F) of the Act, 21 U.S.C. 343(q)(5)(F), because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The Supplement Facts label is not enclosed in a box by using hairlines (21 CFR 101.36(e)(2)).\u003C\u002Fli>\n\t\u003Cli>A heavy bar is not placed under the “Serving Per Container” heading (21 CFR 101.36(e)(6)(i)).\u003C\u002Fli>\n\t\u003Cli>A light bar is not placed under the heading “Amount Per Serving” (21 CFR 101.36(e)(7)).\u003C\u002Fli>\n\t\u003Cli>A heavy bar is not placed under the final other ingredient (21 CFR 101.36(e)(6)(iii)).\u003C\u002Fli>\n\t\u003Cli>The title, “Supplement Facts”, and headings are not bolded (21 CFR 101.36(e)(1)).\u003C\u002Fli>\n\t\u003Cli>There is no provision in the regulation for an Other Ingredients list to appear within the Supplement Facts label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state you will address items within the Supplement Facts label. However, you do not present sufficient evidence to demonstrate corrections. Therefore, your response is insufficient for us to evaluate corrections.\u003C\u002Fp>\n\n\u003Cp>3. Your Ion Gut Support product is misbranded within the meaning of Section 403(q)(1)(A) of the Act, 21 U.S.C. 343(q)(1)(A), because the Supplement Facts label does not include all intended groups as noted in the label directions. If a product is for persons within more than one group, the percent of Daily Value for each group shall be presented in separate columns. Your product’s Supplement Facts labels do not clearly include all the intended groups with the serving size and nutrition information in separate columns in the Supplement Facts label, as required by 21 CFR 101.36. For example, your Frequently Asked Questions found on your website, https:\u002F\u002Fintelligenceofnature.com\u002Fpages\u002Ffrequently-asked-questions#skin, and the product’s bottle labeling provide directions for use for adults and children under 3; however, both those intended groups are not declared on your product’s Supplement Facts labels.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will change the directions of use to indicate oral use only and specify the use is for children four years and older. You do not present sufficient evidence to demonstrate corrections. Therefore, your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>4. Your Ion Gut Support product appears to be misbranded within the meaning of Section 403(s)(2)(B) of the Act, 21 U.S.C 343(s)(2)(B), in that the statement of identity provided on the principal display panel is “mineral supplement”, but there is no mineral declared as a dietary ingredient, in accordance with 21 CFR 101.3(g).\u003C\u002Fp>\n\n\u003Cp>In your response dated September 22, 2023, you state you will update your labeling by March 31, 2024. However, you did not present sufficient evidence to demonstrate corrections. Therefore, we cannot evaluate the sufficiency of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and time within which you will do so. If you believe that your products are not in violation of the Act, include reasoning and any supportive information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Compliance Officer Andrew J. Howard at U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, MD 21117. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have any questions regarding this letter, please contact Andrew J. Howard by telephone, at (410) 779-5125, or by email, at Andrew.Howard@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robin M. Rivers\u003Cbr>\nActing Program Division Director\u003Cbr>\nPhiladephia District Office\u003Cbr>\nHuman &amp; Animal Food East, Division 2\u003Cbr>\nOffice of Regulatory Affairs\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nRobin.Rivers@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDr. Zachary Bush\n\nRecipient Title\n\nOwner\n\nBiomic Sciences, LLC dba ION Intelligence of Nature\n\n4351 Seminole Trail\n\nCharlottesville, VA 22153-2823\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East II\n\nUnited States\n\nMay 9, 2024\n\nWARNING LETTER\n\nCMS #667601\n\nDear Dr. Bush,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4351 Seminole Trail, Charlottesville, Virginia from June 12 through August 31, 2023. Based on inspectional findings and review of the product labels collected during the inspection, as well as review of your website at www.Intelligenceofnature.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the conclusion of the inspection on August 31, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. We address your responses below, when relevant information from such response(s) pertained to a particular issue.\n\nAdulterated Human Drugs\n\nFDA Tested Samples\n\nFDA conducted laboratory testing of a lot of ION Intelligence of Nature Sinus Support Nasal Spray drug product and results demonstrate that this drug product is adulterated within the meaning of section 501(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 351(a)(1), in that it consists in whole or in part of any filthy, putrid, or decomposed substance.\n\nFDA laboratory analysis determined that a sample of your ION Intelligence of Nature Sinus Support Nasal Spray drug product was grossly contaminated with microorganisms. This gross contamination is particularly concerning because your drug product is a nasal spray.\n\nFDA laboratory testing of ION Intelligence of Nature Sinus Support Nasal Spray drug product lot 2302081HGA found gross microbial contamination. The individual sample results varied between 510,000 and up to 1,100,000 colony forming units (CFU)\u002FmL for total aerobic microbial count and between 290 and up to 1,100 CFU\u002FmL for total yeast and mold counts. Therefore, this drug product is adulterated under section 501(a)(1) of the Act.\n\nMicroorganisms identified included Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii), and Paenibacillus sp. The high bioburden in conjunction with the route of administration with this drug product poses a high risk of harm to vulnerable patients.\n\nOn September 22, 2023, the FDA held a teleconference with you. During the teleconference, you agreed to conduct a voluntary recall of all lots of ION Intelligence of Nature Sinus Support Nasal Spray.\n\nOn September 29, 2023, you voluntarily recalled all lots of ION Intelligence of Nature Sinus Support Nasal Spray, ION Sinus, and Restore Sinus Spray products to the consumer level due to microbial contamination identified as Microbacterium sp., Fictibacillus sp., Bacillus sp. (primarily B. malikii), and Paenibacillus sp., as noted on the following FDA website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fbiomic-sciences-issues-voluntary-nationwide-recall-ion-sinus-support-ion-sinus-and-restore-sinus\n\nDrug CGMP Violations\n\nThe inspection of your facility from June 12 through August 31, 2023, identified significant violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Act, 21 U.S.C. 351(a)(2)(B).\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(b)).\n\nYour firm released finished drug product without adequate testing for critical microbial attributes (i.e., testing to ensure absence of objectionable microorganisms). Without appropriate testing of each lot of drug product required to be free of objectionable microorganisms prior to release, you did not have scientific evidence that the lots were free of microbial contamination that is objectionable in view of its intended use. Particularly for a drug product that is intended for use as a nasal spray, it is essential that your drug products are tested for microbial contamination to minimize the risk of patient exposure to significant numbers or harmful species of microorganisms, harmful microbial metabolites and\u002For toxins, and drug spoilage or degradation.\n\nYou also stated during the inspection that you add (b)(4) to numerous drug product formulations to control microbial growth. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating your drug product and cannot be relied on to reduce in-process bioburden during manufacturing. Additionally, long term use of medicinal compounds containing (b)(4) may (b)(4). Levels of (b)(4) exposure that have led to (b)(4) documented and therefore, it is not possible to establish minimum levels that are safe.\n\nIn your September 22, 2023, response, you state that you stopped producing and discontinued sales of the current formulation of ION Intelligence of Nature Sinus Support but plan to market a nasal product in the future. You state that you are revising your written procedures for quality unit (QU) responsibilities, including to specifically establish adequate testing of your finished product and water used in production of your products. You also state that you are revising procedures to ensure all applicable tests impacting the identity, strength, quality, and purity of your products are established and performed.\n\nIn response to this letter, clarify whether you plan to resume manufacturing drug products at this facility in the future for marketing in the United States. We request that you notify this office before you market such drug products.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate QU with responsibilities to ensure adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure:\n\nAdequate procedures that are designed to prevent objectionable microbiological contamination of drug products (21 CFR 211.113(a)).\n\nAdequate testing of components with potential for microbiological contamination that is objectionable in view of its intended use (21 CFR 211.84(d)(6)).\n\nProcedures are followed to adequately establish, review, and approve master manufacturing records prior to use (21 CFR 211.100(a)).\n\nAdequate batch records to document the mixing and packaging of your drug product (21 CFR 211.188).\n\nEstablishment of an adequate stability program to support expiration dating of your drug products (including microbiological attributes) (21 CFR 211.166(a)).\n\nAdequate documentation for QU review and release of drug product. (21 CFR 211.22(a)).\n\nAdditionally, your QU was unaware of the identity of numerous proprietary components used to manufacture many of your drug products, and therefore could not have fulfilled their QU responsibilities to ensure all components meet established specifications for identity, strength, quality, and purity.\n\nYour firm’s quality systems are inadequate. You may refer to FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system1 audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdulterated & Misbranded Dietary Supplements\n\nAdulterated Low Acid Canned Food Dietary Supplements\n\nThe inspection of your facility on June 12 through August 31, 2023, identified serious violations of the Emergency Permit Control regulation Title 21, Code of Federal Regulations (CFR), Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). These violations cause your products to be adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4), in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health.\n\nAs a manufacturer of low acid canned food products, you are required to comply with the Act and the Federal regulations relating to the processing of low-acid foods packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. Regulations specific to the processing of LACF products are described in 21 CFR 108 and 21 CFR 113.\n\n1. You did not register with the FDA as a commercial processor of low-acid foods. A commercial processor of low-acid foods is required, not later than 10 days after first engaging in the manufacture, processing, and packaging of thermally processed low-acid foods in hermetically sealed containers in any state, as defined in section 201(a)(1) of the Act, to register and file a Form FDA 2541 (food canning establishment registration) with the FDA, as required by 21 CFR 108.35(c)(1). However, your firm processes Ion Gut Support, a low-acid food, without registering with the FDA.\n\n2. You must file the scheduled processes with the FDA for each low-acid food in each container size as required by 21 CFR 108.35(c)(2). This filing must occur not later than 60 days after registration and prior to the packing of a new product and include the processing method, type of retort or other thermal processing equipment employed, minimum initial temperatures, times and temperatures of processing, sterilizing value, or other equivalent scientific evidence of process adequacy, critical control factors affecting heat penetration, and source and date of the establishment of the process, for each product in each container size. Specifically, as noted during the inspection, your firm did not file a scheduled process with FDA for your Ion Gut Support product. Further, a scheduled process shall be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of, as required by 21 CFR 113.83\n\nYour response indicates that you have initiated contact with a process authority, (b)(4). We acknowledge that you have initiated actions. However, this violation remains uncorrected.\n\nScheduled process information for low-acid foods processed by retort must be submitted on Form FDA 2541d (Food Process Filing for Low-Acid Retorted Method) and low-acid foods controlled by water activity must be submitted on Form FDA 2541f (Food Process Filing for Water Activity\u002FFormulation Control Method). More information on registration and filing can be found in the publication “Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format” available at http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\n\nViolations of Dietary Supplement CGMPs\n\nThe inspection of your facility from June 12 through August 31, 2023, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Ion Gut Support dietary supplement to be adulterated within the meaning of section 402(g)(1) of the Act, 21 U.S.C. 342(g)(1), because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of dietary supplement CGMP requirements are as follows:\n\n1. You failed to establish identity specifications for each component you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1); component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2); and limits on those types of contamination that may adulterate, or that may lead to adulteration, of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b)(3).\n\nFor your components, you purport to use your Biomic Sciences Component Specification sheets as your specifications for raw components (b)(4), used in the manufacture of your Ion Gut Support. However, these specification sheets do not include identity specifications for any of these components, as required by 21 CFR 111.70(b)(1); do not establish component specifications for (b)(4) or components (b)(4) that will ensure the purity of your Ion Gut Support, as required by 21 CFR 111.70(b)(2); and do not establish contamination specifications for (b)(4), as required by 21 CFR 111.70(b)(3). (b)(4) is susceptible to having contaminants not limited to microorganisms and heavy metals.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated September 22, you state that you are establishing identity component specifications and acceptance criteria using appropriate scientifically valid methods. However, you do not present any supporting evidence for us to evaluate your correction. Your response dated October 31 provides specifications that are for microbial contamination only and does not demonstrate that the requirements of 21 CFR 111.70(b) are met. Your November 15, 2023, and April 24, 2024, responses do not address this citation.\n\n2. You failed to establish product specifications for the identity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). For example, your product label for ION Gut Support lists the content of Humic Extract (from Ancient Soil) in the product as 5 mg; however, you have not established a strength specification for a finished batch of product to ensure that the label claim is met. For each specification you are required to establish and must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75. You must also ensure any tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records, in accordance with 21 CFR 111.95.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. Your October 31, 2023, response provided finished product specifications for ION Gut Support (SPC-01). However, the documents you provided do not demonstrate that you have corrected the above-mentioned deficiencies. Your remaining responses did not address this issue.\n\n3. You failed to quarantine components before you used them in the manufacture of a dietary supplement until quality control could conduct the required review and approval of such components, as required per 21 CFR 111.155(c). Specifically, during the inspection, our investigator observed that you did not place (b)(4) or (b)(4), used in the manufacture of your Ion Gut Support, into quarantine for evaluation and release by Quality Control prior to use. Additionally, you have no records that document you quarantined, sampled, and analyzed select components prior to their use. As an example, you received (b)(4) from your supplier on January 17, 2022. You did not document the quarantine, sampling, or analysis of this component. You used this component on (b)(4), to manufacture (b)(4). You then used this (b)(4) in the manufacturing of Ion Gut Support, 8-oz., Lot 2303301HBA, which was released into commerce.\n\nWe received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your October 31, 2023, response, you state you have established a quarantine area in “(b)(4)” and provided a photograph. However, you did not present any records or evidence that components are being quarantined, sampled, and analyzed in accordance with your written procedure. Your remaining responses did not address this issue. Therefore, your responses fail to demonstrate the sufficiency of your corrective actions.\n\n4. Your batch production record failed to include all the information required under 21 CFR 111.260. Specifically, we reviewed your batch production record for Ion Gut Support and found it failed to contain the following required information:\n\nThe date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained (21 CFR 111.260(c)).\n\nThe identity and weight or measurement of water and (b)(4) components in the (b)(4) and (b)(4) respectively (21 CFR 111.260(e)).\n\nDocumentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the initials of the person responsible for verifying the weight or measure of each component used in the batch, the initials of the person responsible for adding the component to the batch, and the initials of the person responsible for verifying the addition of components to the batch (21 CFR 111.260(j)(2)).\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. In your response dated October 31, 2023, you provided the MPR template for (b)(4). However, it does not include all elements as required in 21 CFR 111.260. Your remaining responses did not address this issue.\n\n5. You failed to establish and follow written procedures for calibrating instruments and controls you use in manufacturing or testing a component or dietary supplement, as required by 21 CFR 111.25(a). Specifically, you have not established written procedures for calibrating your (b)(4), which you use in the manufacturing or testing of your Ion Gut Support.\n\nWe have received your responses dated September 22, October 31, and November 15, 2023; and April 24, 2024. However, none of your responses provided documentation to demonstrate that you have established and followed written procedures for calibrating your (b)(4). Therefore, we cannot evaluate the sufficiency of your corrective actions.\n\nMisbranding of Dietary Supplement Products\n\nIn addition, we reviewed your product labels collected during the inspection and have determined the Ion Gut Support dietary supplement product you manufacture and distribute is misbranded under section 403 of the Act, 21 U.S.C. 343, because it does not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Ion Gut Support dietary supplement products are misbranded within the meaning of Section 403(i)(2) of the Act, 21 U.S.C. 343(i)(2), in that the product labels fail to declare all the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4.\n\nThe Supplement Facts panel of your product identifies “Humic Extract” as the active ingredient with only “Purified water” as the other ingredient. We reviewed and collected your batch production records, which document formulation, of all sizes of your Ion Gut Support product. According to your batch production records, your Ion Gut Support includes the following ingredients: (b)(4) purified water, (b)(4).\n\nEach ingredient must be declared by the common or usual name in descending order of predominance within the ingredient list unless an exemption is provided in 21 CFR 101.100, or a collective (generic) name is provided in 21 CFR 101.4.\n\nIn your response, you state your components, other than humic extract, are processing aids to create the extraction. However, you provide no evidence these components are not present in the finished product. Further, the (b)(4) product (which is a product that consists of: (b)(4) are added after the extraction process. Thus, they are not processing aids as defined under 21 CFR 101.100(a)(3)(ii). Therefore, your response is inadequate.\n\n2. Your Ion Gut Support products are misbranded under 403(q)(5)(F) of the Act, 21 U.S.C. 343(q)(5)(F), because the presentation of the nutrition information on the labeling of each product label does not comply with 21 CFR 101.36. For example:\n\nThe Supplement Facts label is not enclosed in a box by using hairlines (21 CFR 101.36(e)(2)).\n\nA heavy bar is not placed under the “Serving Per Container” heading (21 CFR 101.36(e)(6)(i)).\n\nA light bar is not placed under the heading “Amount Per Serving” (21 CFR 101.36(e)(7)).\n\nA heavy bar is not placed under the final other ingredient (21 CFR 101.36(e)(6)(iii)).\n\nThe title, “Supplement Facts”, and headings are not bolded (21 CFR 101.36(e)(1)).\n\nThere is no provision in the regulation for an Other Ingredients list to appear within the Supplement Facts label.\n\nIn your response, you state you will address items within the Supplement Facts label. However, you do not present sufficient evidence to demonstrate corrections. Therefore, your response is insufficient for us to evaluate corrections.\n\n3. Your Ion Gut Support product is misbranded within the meaning of Section 403(q)(1)(A) of the Act, 21 U.S.C. 343(q)(1)(A), because the Supplement Facts label does not include all intended groups as noted in the label directions. If a product is for persons within more than one group, the percent of Daily Value for each group shall be presented in separate columns. Your product’s Supplement Facts labels do not clearly include all the intended groups with the serving size and nutrition information in separate columns in the Supplement Facts label, as required by 21 CFR 101.36. For example, your Frequently Asked Questions found on your website, https:\u002F\u002Fintelligenceofnature.com\u002Fpages\u002Ffrequently-asked-questions#skin, and the product’s bottle labeling provide directions for use for adults and children under 3; however, both those intended groups are not declared on your product’s Supplement Facts labels.\n\nIn your response, you state you will change the directions of use to indicate oral use only and specify the use is for children four years and older. You do not present sufficient evidence to demonstrate corrections. Therefore, your response is inadequate.\n\n4. Your Ion Gut Support product appears to be misbranded within the meaning of Section 403(s)(2)(B) of the Act, 21 U.S.C 343(s)(2)(B), in that the statement of identity provided on the principal display panel is “mineral supplement”, but there is no mineral declared as a dietary ingredient, in accordance with 21 CFR 101.3(g).\n\nIn your response dated September 22, 2023, you state you will update your labeling by March 31, 2024. However, you did not present sufficient evidence to demonstrate corrections. Therefore, we cannot evaluate the sufficiency of your corrective actions.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of the receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and time within which you will do so. If you believe that your products are not in violation of the Act, include reasoning and any supportive information for our consideration.\n\nYour written reply should be directed to Compliance Officer Andrew J. Howard at U.S. Food and Drug Administration, 11155 Dolfield Boulevard, Suite 117, Owings Mills, MD 21117. An emailed response is also acceptable. Files greater than 100 megabytes may be submitted as smaller files in separate emails. If you have any questions regarding this letter, please contact Andrew J. Howard by telephone, at (410) 779-5125, or by email, at Andrew.Howard@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRobin M. Rivers\n\nActing Program Division Director\n\nPhiladephia District Office\n\nHuman & Animal Food East, Division 2\n\nOffice of Regulatory Affairs\n\nU.S. Food and Drug Administration\n\nRobin.Rivers@fda.hhs.gov\n\n___________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Biomic Sciences, LLC dba ION Intelligence of Nature","biomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiomic-sciences-llc-dba-ion-intelligence-nature-667601-05092024","2026-10-26T08:08:05.177812+00:00","2024-05-28","667601","Dr. Zachary Bush","2026-08-20T00:03:55.93+00:00","2024-05-09",7,{"510k":159,"classification":160,"enforcement":161,"event":162,"event_backfill":163,"pma":164,"warning_letter":165},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]